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ABSTRACT 
       Apparent absorption of isoflavones varies greatly among individuals, but is 
relatively stable within an individual. We hypothesized that high urinary isoflavone excreters 
would show less plasma non-HDL cholesterol than low isoflavone excreters after soy protein 
feeding. Fifty Golden Syrian hamsters were fed a high fat/casein diet (n = 10) or a high 
fat/soy protein diet (n = 40) for 4 wk. Two distinct urinary isoflavone excretion phenotypes 
were identified using a pairwise correlation plots analysis, or using a hierarchical cluster test. 
High isoflavone excreters showed significantly greater urinary isoflavones (p<0.05) than did 
low isoflavone excreters. High urinary isoflavone excreters had significantly less non-HDL 
cholesterol than did the low isoflavone excreters or casein-fed controls (p < 0.05). Urinary 
isoflavone excretion phenotypes predicted the cholesterol-lowering efficacy of soy protein.  
Isoflavone absorbability, probably due to gut microbial ecology, is an important controllable 
variable in studies of effects of soy protein on blood lipids.  
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GENERAL INTRODUCTION  
 
Introduction 
               
       Isoflavones are a class of phytoestrogens including genistein, daidzein, glycitein, 
and their various glucoside derivatives, found mainly in soybeans. Because isoflavones are 
structurally similar to mammalian estrogens, interest has focused primarily on their effects on 
hormone-dependent conditions. Some studies have provided evidence for a potentially 
protective role for isoflavones in cardiovascular disease, breast cancer, prostate cancer, 
osteoporosis, and menopausal symptoms.  
       Isoflavone bioavailability is complex and shows a wide range of interindividual 
variability. Many human studies and animal models have been established to study 
bioavailability of isoflavones. Some focused on understanding how isoflavones are 
metabolized in the body including plasma kinetics as well as urinary and fecal excretion. We 
know that isoflavone glucosides undergo cleavage of their sugar moiety by intestinal β-
glucosidases to be absorbed mostly in the small intestine in humans—not sure about animal 
models. After absorption, isoflavones undergo intestinal and hepatic biotransformation to 
mainly glucuronide conjugates. Most of the conjugates are excreted through bile back into 
the intestine. Deconjugation is necessary for reabsorption. Bacteria are also responsible for 
degrading and producing metabolites of isoflavones. Establishment of phenotypes of 
isoflavone bioavailability is important to understand the specific roles that isoflavones may 
play in human health. 
      Soy isoflavones have gained considerable attention for their potential role 
preventing the development of atherosclerosis and subsequent cardiovascular disease (CVD). 
Potential mechanisms by which soy isoflavones might prevent atherosclerosis include 
beneficial effects on serum lipid profiles, antioxidant properties, blood vessel function, blood 
pressure, inhibiting thrombus formation and suppressing smooth muscle cell proliferation and 
migration as well as improving vascular reactivity.    
    The component or components of soy that are responsible for improvements in 
lipid metabolism have been investigated and their specific actions debated. A significant 
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reduction in LDL cholesterol in hypercholesterolemics is not evident among some recent 
trials. A recent review did not support the current research on the effect of soy protein or 
iosflavone supplements on the beneficial effect of isoflavones on human plasma lipoproteins.   
                 Furthermore, the mechanism for the cholesterol lowering ability of soy protein and 
isoflavone is the topic of many hypotheses and the mechanisms by which isoflavones alter 
plasma lipoprotein concentrations are still matters of debate. It is known that reduced LDL-
cholesterol concentrations associated with estrogen intake are a direct result of increased 
LDL receptor activity, decreased intestinal absorption of cholesterol as well as affecting 
sterol regulatory element binding proteins which regulate genes related to LDL receptor 
expression.  
     The objective of this study was to identify urinary isoflavone excretion phenotypes 
in a hamster model using two statistical methods and to characterize phenotypic stability over 
4 wks. Secondly, we investigated the effects of the distinct isoflavone phenotypes on the 
level of plasma lipids. Third, we also quantified the relationships between the level of urinary 
and fecal isoflavone excretions and plasma lipids. 
 
 
Thesis Organization 
 
     This thesis contains a general introduction, a literature review focusing mainly on 
health-effects, bioavailability and metabolism of isoflavones, and mechanism of lowerng 
cholesterol of isoflavone. The paper entitled “High urinary isoflavone excretion phenotype 
decreases plasma cholesterol in golden Syrian hamsters fed soy protein” has been published 
by the Journal of Nutrition.  
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LITERATURE REVIEW                      
 
A. Molecular Structure and biological properties of isoflavone     
 
      Isoflavones are a class of phytoestrogens in soybeans: including genistein, 
daidzein, and glycitein. They are present as β-glucosides, 6”-O-malonyl-β-glucosides, and 
6”-O-acetyl-β-glucosides as well as the aglucon forms. Genistein and daidzein have been 
found in relatively high concentration in soybeans and most soy-protein products, whereas 
much lower amounts of glycitein are present in soybeans (Wang and Murphy. 1994 and 
1996). The basic structural feature of isoflavone compounds is the flavone nucleus, which is 
composed of two benzene rings (Figure 1). The chemical structures of 17β-estradiol and 
equol (a daidzein metabolite) are so similar that they superimpose (Figure 2).     
              Daidzein   
              Genistein  
               Glycitein    
                             
                           Figure 1. Molecular structure of soy isoflavone 
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                         17ß-Estradiol  
                              
             Equol 
 
 
                       Figure 2. The chemical structures of 17β-estradiol and equol 
 
 Isoflavones have an intermediate solubility meaning they are not soluble in water or 
in very hydrophobic solvents. They are soluble in alcoholic solvents but the solubility is low. 
Also isoflavones can be ionized at high pH which affects their recovery from certain foods 
(Rickert et al. 2004). Soy protein concentrates contain insignificant amounts of isoflavones 
because they are obtained through alcohol extraction which removes isoflavones from soy 
(Wang and Murphy. 1994). The aqueous processing of tofu and the dilution of soy protein 
with other ingredients in soy milk and second-generation soy products explain the reduced 
isoflavone content present in these products (Anderson et al. 1995). 
              Isoflavones are traditionally consumed in relatively high amounts by some Chinese 
populations. Liu et al. (2004) reported average intake of soy foods and isoflavones was 23.5 
g/d and 8.9 mg/d by 1,188 subjects in Gansu Province and Hebei Province of China using 
food frequency questionnaires (FFQ). In contrast, while it was reported that the intake of soy 
isoflavones by women in the Netherlands (aged 50–69 y, n = 17,357) and United States of 
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America (964 postmenopausal Caucasian women in the Framingham Offspring Study using 
the Willett food-frequency questionnaire) was estimated to be less than 1 mg/d (De Kleijn et 
al. 2001; Boker et al. 2002). Because isoflavones are structurally similar to the mammalian 
estrogens, interests have focused primarily on their effects on hormone-dependent conditions. 
Epidemiologic studies show potentially protective roles for isoflavones in cardiovascular 
disease, breast cancer, prostate cancer, osteoporosis, and menopausal symptoms (Duncan et 
al. 2003).                 
                   
B. Metabolism of Isoflavones         
         
   Several studies have been conducted to investigate the metabolism of isoflavones. 
The actual process of isoflavone absorption is still somewhat obscure. The molecular weights 
of isoflavone aglycones are 254, 270, and 284 g/mol for daidzein, genistein, and glycitein, 
respectively, which are neither hydrophilic nor lipophilic. Due to their low molecular weight, 
isoflavones could be absorbed through diffusion (Birt et al. 2001) and converted to aglycones 
by membrane-bound or bacterial β-glucosidases in the intestinal tract (Day et al. 1998). Day 
et al. (1998) investigated the ability of human small intestine and liver extracts to flavonoid 
and isoflavonoid glycosides. Samples of small intestine and liver were surgically obtained 
from patients undergoing gastrointestinal surgery. These compounds were deglycosylated by 
extracts from both tissues at 37°C incubation for up to 90 min. 
  The absorption and degradation processes of isoflavones may be influenced by the 
presence of the gut microflora. Bacteria play an important role in this cleavage process 
through β-glucosidase or β-glucuronidase activity. In an early study, Hawksworth et al. 
(1971) showed that a variety of bacteria possess these enzymatic activities using in vitro 
incubation of groups of bacteria with various sugars, all differing in their glycosidic bonds 
from one another and measuring the different sugar breakdown over time. β-glucosidases 
have been found in Enterococci and to a lesser extent in Lactobacilli, Clostridia, Bacteroides 
and Bifidobacteria strains.  β-glucuronidase activity is mostly due to Enterobacteria and to a 
much lesser extent by Clostridia and Bacteroides. Day et al. (2000) indicated that lactase 
phlorizin hydrolase (LPH), a membrane-bound, β–glucosidase purified from mammalian 
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(sheep) small intestine was able to cleave the sugar moiety of daidzin and genistin with a 
greater Vmax for genistin (~2.8 U/mg LPH) than daidzin (~0.9 U/mg LPH). This cleavage 
process apparently delayed the absorption compared to ingested isoflavone aglycones. 
    In in vitro studies, Schoefer et al. (2002) showed that the incubation of E. ramulus 
with 0.5 mM genistein-7-O-glucoside yielded two metabolites with retention times of 26.0 
min (Gg1) and 34.7 min (Gg2). Gg1 was identified by HPLC and LC–MS as 2-(4-
hydroxyphenyl)-propionic acid. Comparison of the retention time and UV-spectrum of Gg2 
with the reference substance revealed its identity with genistein. The ability of E. ramulus to 
hydrolyze the glycosidic bond of genistein-7-O-glucoside is in agreement with data collected 
by Schneider & Blaut (2000). E. ramulus was reported to cleave off the sugar moiety of 
flavone and flavonol glycosides in positions 3 and 7 of the ring system. The ability of an 
isolated bacterial species to hydrolyze the glycosidic bond of genistein-7-O-glucoside and 
daidzein-7-O-glucoside has been also reported for Escherichia coli HGH21 and the newly 
isolated strain HGH6 (Hur et al. 2000). Furthermore, Tsangalis et al. (2002) tested five 
strains of Bifidobacterium to screen β-glucosidases activity using p-nitrophenyl-b-D-
glucopyranoside as the substrate, and using selected strains to ferment soymilk. Enumeration 
of viable Bifidobacteria and quantification of isoflavones using HPLC were performed at 0, 
12, 24, 36, and 48 h of incubation. Four strains produced β-glucosidase. B. pseudolongum 
and B. longum-a displayed the best growth in soymilk, with an increase of 1.3 log10 
CFU/mL after 12 h. B. animalis, B. longum-a, and B. pseudolongum caused hydrolysis of 
isoflavone malonyl-, acetyl- and β-glucosides to form aglycones. Fermentation of soymilk 
with Bifidobacterium sp. resulted in a significant increase in the concentration of aglycones. 
In conclusion, the cleavage of isoflavone glucosidic form was required for the absorption in 
the intestinal tract. After absorption the predominant forms of isoflavones in plasma and 
urine are the conjugates isoflavone sulfates and glucuronides.              
   Isoflavones undergo endogenous biotransformation by UDP-
glucuronosyltransferase (UGTs) and sulfotransferases in the intestinal mucosa, liver, and 
other organs, which modify their chemical structure and solubility, thereby influencing 
distribution, storage, and excretion (Birt et al. 2004). Glucuronide and sulfate conjugates 
made up about 70-80% and 20% of total isoflavone in urine, respectively and 50-60% and 
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20-30% in plasma, respectively in women fed soymilk (n=6) (Zhang, 2000). In addition, 
greater amounts of isoflavone aglucon were recovered from 0-24 h plasma samples (~20-
25% ingested dose) compared to 0-24 h urinary excretion (<10% ingested dose). Sfakianos et 
al. (1997) reported the more than half of ingested genistein was excreted in the bile after 
conjugation. Sfakianos et al. (1997) used anesthetized female rats with biliary cannulas. 
Genistein infused into the duodenum was recovered as 7-O-β-genistein glucuronide and 75% 
of the infused dose was recovered within 4 h. Moreover infusion of genistein glucuronide in 
the duodenum resulted in a slower biliary excretion of the same compound, indicating that 
like glucosides, isoflavones endogenously conjugated have to be cleaved prior to 
reabsorption, either by intestinal or microbial enzymes. 
   In order to be reabsorbed after biliary excretion, isoflavone conjugates must be 
cleaved. The same applies to any isoflavone glucosides that might have arrived intact in the 
ileum or large intestine. Isoflavones which are excreted back into the intestine will be 
deconjugated by gut microbial glucuronidase and sulfatase to release the aglycone form, part 
of it being possibly reabsorbed through enterohepatic circulation (Sfakianos et al. 1997). 
Isoflavones not undergoing this process are subject to microbial degradation and metabolite 
formation, while the rest undergoes fecal excretion. 
   In a summary about the data described above, humans and animals share many 
similarities in absorption, biotransformation, and excretion of isoflavones. Gut 
microorganisms play an important part in isoflavone metabolism. Furthermore, gut 
microflora are also responsible for converting isoflavones into metabolites. 
   Several candidate bacteria for daidzein metabolism have been suggested, for 
example, a Clostridium sp. (Hur et al. 2002) and E. ramulus (Schoefer et al. 2002) 
metabolized daidzein to O-DMA in vitro, and equol has been found in soymilk fermented 
with some strains of Bifidobacterium (Tsangalis et al. 2002).   
   Hur et al. (2002) has reported that anaerobic bacterium was involved in the ring 
cleavage of daidzein to produce O-DMA. A gram-positive anaerobic bacterium, strain HGH 
136, capable of conversion of the isoflavonoid daidzein, was isolated and identified as a 
Clostridium sp. The bacterium cleaved the C-ring of daidzein to produce O-
demethylangolensin (O-DMA). The identity of the metabolite was confirmed by liquid 
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chromatography-mass spectrometry and NMR using synthetic O-DMA as a standard. The 
bacterium incubated with synthetic dihydrodaidzein also produced O-DMA. After 3 days of 
incubation, 28% of added daidzein and 12% of added dihydrodaidzein were converted to O-
DMA. E. ramulus, a flavonoid-degrading anaerobic bacterium from the human 
gastrointestinal tract, was tested by Schoefer et al. (2002) for its ability to transform the 
isoflavonoids daidzein, genistein-7-O-glucoside (genistin), genistein. As a result, daidzein 
was also degraded to O-desmethylangolensin, the corresponding metabolite to 6'-hydroxy-O-
desmethylangolensin. Genistein was completely degraded by E. ramulus via 6'-hydroxy-O-
desmethylangolensin to 2-(4-hydroxyphenyl)-propionic acid. Dihydrogenistein was neither 
observed as an intermediate in this transformation nor converted itself by growing cells or 
cell-free extracts of E. ramulus. Genistein-7-O-glucoside was partially transformed by way 
of genistein to the product 2-(4-hydroxyphenyl)-propionic acid. They suggested the hydroxyl 
group in position 6' of O-desmethylangolensin is crucial for further degradation. Although in 
Tsangalis et al. (2002) study, five strains of Bifidobacterium were screened for β-glucosidase 
activity, they also found daidzein was transformed to equol using selected strains to ferment 
soymilk. It has been suggested that other bacteria, including Escherichia coli, Bacteroides 
ovatus, Ruminococcus productus, or Streptococcus intermedius (Hur et al. 2000; Ueno et al. 
2002) could be involved in daidzein metabolism. Recently, specific bacteria responsible for 
isoflavone metabolism in humans have been identified by Renouf et al. (2005). They 
established that Golden Syrian hamsters may be a good model to study bioavailability of 
isoflavones and their possible health promoting effects. They showed that high fecal 
isoflavone degradation rate was related with distinct fecal bacterial species. Thirty three 
healthy adult subjects’ fresh feces were incubated anaerobically with isoflavones to identify 
degradation rates using HPLC and fecal bacterial 16S rDNA sequences were performed by 
PCR-DGGE. Cluster analysis and DGGE analysis indicated that high genistein and glycitein 
degraders shared 5 DNA bands of greater intensity than found in feces of low degraders. 
Three species, Bacteroides, Prevotella genus and Clostridiales were identified by sequencing 
of 16S rDNA from the interest bands. Furthermore Bacteroides ovatus, Bacteroides 
acidifaciens, Eubacterium ramulus, Clostridium orbiscindens, and Tannerella forsythensis 
were identified as the major human gut microbial species that degraded isoflavones under 
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both nutrient rich and poor in vitro systems. They concluded that bacterial species with 
greater amounts in high degraders which also existed in low degraders may be predictors for 
gut microbial degradation and overall bioavailability of isoflavones. 
   In a summary, gut microflora play a crucial role in isoflavone metabolism. The 
absorption and degradation of isoflavones are very complicated. Some specific fecal bacterial 
species may be responsible for these processes.  The main reason for apparent variability in 
fecal isoflavone degradation among individuals is the different amount of bacterial 
population. However, the mechanism how these bacterial species convert isoflavones to 
metabolites remains further attention.       
    
C. Isoflavones and cardiovascular disease risk  
    
      Isoflavones have gained considerable attention for their potential role in 
preventing the development of atherosclerosis and subsequent cardiovascular disease (CVD). 
Atherosclerosis is a main cause of human disease and death worldwide. Atherogenesis is a 
complex process, with multiple mechanisms contributing to its initiation and progression 
including infections, inflammation, or autoimmunity in pathogenesis of the disease 
(Leinonen et al. 2002). Susceptibility to atherosclerosis is determined by a combination of 
genetic and environmental factors, including diet. Consumption of diets rich in soy protein 
has been claimed to protect against the development of atherosclerosis (Anthony et al. 1997). 
Isoflavones exert several anti-atherogenic effects through which soy protein and say 
isoflavones may protect against CVD have been proposed (Anthony et al. 1997; Yamakoshi 
et al. 2000). In a cohort study of 75,000 Chinese women aged 40–70 y at the baseline survey 
from 1997 to 2000, the clear inverse dose-response relationship between soy food intake and 
risk of total CHD observed for women in the highest intake ( 11.2 g/d) vs. the lowest (<4.5 
g/d) quartile of total soy protein has been reported (Zhang et al. 2003). A recent analysis 
assessing eight different randomized controlled trials using human subjects indicated that 
intake of isoflavones has LDL cholesterol-lowering effects independent of soy protein intake 
(Zhuo et al. 2004). 
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a. Effects of isoflavones on serum lipid profiles 
 
      High total cholesterol and LDL cholesterol levels correlate with cardiovascular 
disease. Elevated cholesterol levels contribute to the formation of atherosclerotic plaques and 
eventually to thrombosis or myocardial infarction. Management of cholesterol levels is an 
essential part of treating cardiovascular disease. Soy intake has been shown to lower 
cholesterol levels and thereby reduce the risk of developing atherosclerosis. A meta-analysis 
of 38 controlled clinical trials reported that intake of soy protein was associated with a 
significant hypocholesterolemic effect which included a reduction in serum concentrations of 
total cholesterol, LDL cholesterol and triacylglycerols, and a nonsignificant increase in HDL 
cholesterol (Anderson et al. 1995). Subsequently, many well-controlled studies explored the 
soy protein hypothesis with greater specificity (Crouse et al. 1999; Lichtenstein et al. 2000; 
Merz-Demlow et al. 2000; Gardner et al. 2001 and Wangen et al. 2001) and found more LDL 
cholesterol reduction in hypercholesterolemic subjects than in those with lower LDL      
cholesterol levels. On the other hand, the component or components of soy that are 
responsible for improvements in lipid metabolism have been investigated and their specific 
actions debated. A meta-analysis concluded that isoflavones did not affect plasma lipid 
concentrations (Weggemans et al. 2003). A recent review from American Heart Association 
Science Advisory did not support the current research on the effect of isolated soy protein 
with isoflavones on LDL cholesterol concentrations (Sacks et al. 2006).      
        The topic of cholesterol lowering of soy protein and soy isoflavone is 
controversial and a subject of current debate. Some studies have demonstrated different 
results when intake of intact high isoflavone-containing soy protein was compared with 
intake of low isoflavone-containing soy supplemented with added isoflavones (Erdman et al. 
2004). Some studies have mentioned that isoflavone-rich soy protein did not improve blood 
lipid profile (Dent et al. 2001; Blair et al. 2002; Lin et al. 2004). These studies have been 
conducted to investigate whether the hypocholesterolemic effect is attributable to the soy 
protein or the high content of the phytoestrogenic isoflavones in soy. Results did not show a 
specific effect of isoflavones on LDL or HDL cholesterol.  
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     Dent et al. (2001) reported that a dietary intake of soy protein for six months did 
not improve circulating lipid and lipoprotein concentrations for either isoflavone-rich soy 
(80.4 mg/d aglycone components; n=24) or isoflavone-poor soy (4.4 mg/d aglycone 
components; n=24) in normocholesterolemic perimenopausal women or in perimenopausal 
women (n=30) who were mildly hypercholesterolemic.         
     Several studies showed isoflavones had no effect on cholesterol lowering in some 
animal trials. A meta-analysis reported that isoflavones did not affect blood lipid 
concentrations. Weggemans et al. (2003) investigated the specific effect of soy-associated 
isoflavones on cholesterol concentrations in well-controlled trials substituting soy protein 
with dairy or animal protein. They collected the data from MEDLINE searches (1995 - 1996 
June 2002) and reviewing reference lists. Studies were included if they had a control group or 
treatment, experimental diets only differed in the amounts of soy protein and isoflavones and 
were each fed for at least 14 days. A total of 10 studies met these criteria, providing 21 
dietary comparisons, including 959 subjects (336 men and 623 women), average age from 41 
to 67 y and baseline cholesterol concentration from 5.42 to 6.60 mmol/l. The intake of soy-
associated isoflavones was 1-95 mg/day and the intake of soy protein was 19-60 g/day. No 
definite evidence was found in feeding daily 36 g soy protein with 52 mg soy-associated 
isoflavones on average to decrease low-density lipoprotein (LDL) cholesterol and increase 
high-density lipoprotein (HDL) cholesterol compared with control group. No dose-response 
relation existed between soy-associated isoflavones intake and changes in LDL cholesterol or 
HDL cholesterol.  
   Recently, a review did not support the current research on the effect of soy protein 
and isoflavones on plasma LDL cholesterol concentrations from American Heart Association 
Science Advisory. Sacks et al. (2006) assessed the more recent work published on isolated 
soy protein with isoflavones in the majority of 22 randomized trials as compared with milk or 
other proteins. They showed no significant effects on HDL cholesterol, triglycerides, 
lipoprotein, or blood pressure. Especially among 19 studies of soy isoflavones, the average 
effect on LDL cholesterol and other lipid risk factors was very small. Also, soy protein and 
isoflavones have not been shown to lessen vasomotor symptoms of menopause, blood 
pressure and postmenopausal bone loss. The efficacy of soy isoflavones for preventing or 
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treating cancer of the breast, endometrium, or prostate was not evident. These studies 
concluded consumption of soy-associated isoflavones was not related to changes in LDL or 
HDL cholesterol and the data raised some questions about the clinical importance of the 
hypocholesterolemic effects observed.  
In conclusion, there are many factors that influence the extent to which isoflavones 
play an efficacy of protecting against CVD. Basic diet ingredients, food matrix, cholesterol 
baseline or isoflavone dosage, experimental duration, subject age and sex and gut transit time 
may be involved in modulating processes related to CVD. The most important factor which 
these studies did not attempt to control was the interindividual variability in isoflavone 
bioavailability. A lack of efficacy of isoflavones and soy protein feeding may occur in 
populations that had lesser absorption of isoflavones while the apparent protective effects of 
isoflavones on cholesterol-lowering may tend to have occurred in individual with higher 
absorption of isoflavones.  
On the other hand, soy intake has been shown to lower cholesterol levels and thereby 
reduce the risk of developing atherosclerosis. The beneficial effects of soy intake on plasma 
lipoprotein levels led to FDA approval of a health claim that "25 g of soy per day, as part of a 
diet low in saturated fat and cholesterol, may reduce the risk of heart disease." This health 
claim and other media publicity are promoting intake of both soy food products and 
isoflavone-containing soy supplements. Many studies have provided substantial evidence to 
confirm the cholesterol lowering effect of soy protein and soy isoflavone (Potter et al. 1998; 
Anthony et al. 1997; Lucas et al. 2001; Lukaczer et al. 2005).  
 Potter et al. (1998) investigated the effects of soy protein (40 g/d) containing 
moderate and higher concentrations of isoflavones on blood lipid profiles, mononuclear cell 
LDL receptor messenger RNA, and bone mineral density and content in 66 free-living, 
hypercholesterolemic, postmenopausal women during a 6-mo, parallel-group, double-blind 
trial. They reported non-HDL cholesterol for both groups was reduced compared with the 
control group besides significant increasing bone mineral content and density in the lumbar 
spine. They concluded that intake of soy protein at both isoflavone concentrations for 6 mo 
may decrease the risk factors associated with cardiovascular disease in postmenopausal 
women.  
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To distinguish the relative contributions of the protein moiety versus the alcohol-
extractable phytoestrogens for cardiovascular protection, Anthony et al. (1997) studied 3 
group of young male cynomolgus macaques fed a moderately atherogenic diet. The groups 
differed only in the source of dietary protein, which was either casein/lactalbumin (casein, 
n=27), soy protein with the phytoestrogens intact (soy+, n=27), or soy protein with the 
phytoestrogens mostly extracted (soy-, n=28). The diets were fed for 14 months. Animals fed 
soy+ had significantly lower total and LDL plus VLDL cholesterol concentrations compared 
with the other two groups. They indicated the beneficial effects of soy protein on 
atherosclerosis appear to be mediated primarily by the phytoestrogen component. 
In a hamster study, Lucas et al. (2001) reported ethanol-extracted soy protein isolate 
alone does not lower serum cholesterol. Ethanol-extracted soy protein isolate (SPe) was fed 
to both sham-operated and ovariectomized 48 six-month-old female Golden Syrian hamsters 
for 70 d. Ovariectomy significantly increased total serum cholesterol and non-HDL 
cholesterol concentrations in casein-based or SPe-based diets compared with sham hamsters. 
Still, ovariectomy SPe-based diets did not decrease serum total cholesterol (7.3 ± 0.3 vs. 6.6 
± 0.3 mmol/L) and non-HDL cholesterol (3.6 ± 0.2vs. 3.3 ± 0.2 mmol/L) compared to casein-
based diets. Although these findings confirmed the ovariectomized hamster as a model of 
postmenopausal hypercholesterolemia, the components of protein fractions does not play 
cholesterol lowering role in soy protein.  These data were in agreement with the data 
observed by Anthony et al. (1997) in which soy protein with the phytoestrogens mostly 
extracted (soy-) did not mediate beneficial effects of soy protein on cholesterol lowering. In 
another animal study, Song et al. (2003) fed sixty male and 60 female golden Syrian hamsters 
in six treatments for 10 weeks with dietary isolated soy protein (ISP), ethanol-extracted ISP 
(ISP (-)), soygerm or soygerm extract (containing large amounts of daidzein and glycitein 
and little genistein), daidzein and casein diet group. Hamsters fed ISP, ISP (-), daidzein, 
soygerm, and soygerm extract had significantly less plasma total cholesterol, less non-HDL 
cholesterol and less non-HDL/HDL cholesterol ratios compared with hamsters fed casein. 
They concluded that soy protein with or without isoflavones, soygerm and soygerm extract, 
and daidzein lessened plasma cholesterol to an approximately equal extent. Soy protein 
alone, varying mixtures of isoflavones, and other extractable components of soy were 
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responsible for cholesterol-lessening effects of soy foods, mainly due to their effects to lessen 
LDL cholesterol.   
Furthermore, isoflavones from kudzu and red clover also were investigated by 
Lukaczer et al. (2005) in a pilot study to assess the effect of an isoflavone nutritional   
supplement on menopausal symptoms and markers of breast cancer and CVD risk. Twenty-
five menopausal women suffering from severe hot flushes and night sweats completed a 12-
week intervention using this combination isoflavone nutritional supplement. They observed a 
46% decrease in reported hot flushes. Two markers of CVD risk, the ratio of total cholesterol 
to high-density lipoprotein (HDL) cholesterol and homocysteine, showed modest 
improvement. A proposed marker of breast cancer risk, the ratio of 2-hydroxyestrone to 16 
alpha-hydroxyestrone, also showed a statistically significant improvement. They reported 
from this pilot trial that with isoflavone nutritional supplementation may significantly relieve 
the most troubling symptoms of menopause, as well as confer some chemopreventive and 
cardioprotective benefits.  
    In order to distinguish the main component of the cholesterol-lowering effect of 
soy protein, a greater effect of cholesterol-lowering was seen with increased isoflavone 
intake. Several studies focused on the threshold dose of the isoflavone effect in humans and 
animals models (Crouse et al. 1999, Merz-Demlow et al. 2000, Wangen et al. 2001, Lucas et 
al. 2003, Zhuo et al. 2004). Crouse et al. (1999) fed beverages containing either 25g 
casein/day, 25g soy protein/day at: 3, 27, 37, or 62 mg total isoflavones (0.15, 1.4, 1.95 and 
3.3µmol/kg BW/d) for 9 weeks in moderately hypercholesterolemic men and women. The 
highest isoflavone group fed 62 mg total isoflavones/d significantly decreased the total and 
LDL cholesterol (4% and 6% reduction) compared with the casein group. This study 
determined a threshold effect of isoflavones on cholesterol-lowering dose-response. 
Afterwards, Merz-Demlow et al. (2000) used three isolated soy protein (ISP) consumption 
doses: <10mg/d (control; 0.5µmol/kg BW/d), ~65mg/d (low isoflavone; 3.4µmol/kg BW/d), 
or ~130mg/d (high isoflavone; 6.8µmol/kg BW/d) in different phases of a women’s 
menstrual cycle (early follicular, midfollicular, periovulatory and midluteal phases). LDL-C 
concentrations were lowered only in high isoflavone diet compared to control in the 
midfollicular (2.20±0.04 vs. 2.38±0.04mmol/L) and periovulatory (2.07±0.05 vs. 
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2.3±0.05mmol/L) phases. The same doses made by Merz-Demlow et al. (2000) were 
investigated in 18 postmenopausal women with a 93-d crossover study by Wangen et al. 
(2001). Subsequently, the concentrations of LDL-cholesterol in three groups were lowered 
gradually (3.22±0.05mmol/L vs. 3.05±0.05mmol/L vs. 3.01±0.05mmol/L). The results 
showed that the high isoflavone significantly lowered LDL-C cholesterol compared to 
control while the low isoflavone was no different from control or high isoflavone.  
    Similar results were obtained from six-month-old female Golden Syrian hamsters, 
In ovariectomized (ovx) hamsters, fed three different isoflavone doses compared with 
control, by Lucas et al. (2003) the cholesterol-lowering effects of isoflavones became more 
significant (7.8%, 11.8%, and 19.6% reductions in total cholesterol) for ovx + 9.5 (low-dose), 
19 (medium-dose), or 38 (high-dose) mg isoflavones/kg diet, whereas the doses were less 
than that of Wangen et al. (2001). Alternatively, this study also explained how isoflavones 
play a role in soy protein’s effect.  
Not only may isoflavones have an important role, but it was also observed that only a 
minimal dose of 96 mg isoflavone/d (~5µmol/kg BW/d) was required to observe an effect in 
a meta-analysis of 8 human studies by Zhuo et al. (2004). LDL-C levels were significantly 
decreased in both normo-and hypercholesterolemic subjects at 96mg isoflavone (0.14 and 
0.18mmol/L decrease, respectively) while baseline hypercholesterolemia was lowered more 
than normocholesterolemia (p=0.0008 vs. 0.03) by the effect of isoflavones.  
More recently, a review also supported the current research on the effect of soy 
protein and isoflavones on plasma LDL cholesterol concentrations. Reynolds et al. (2006) 
collected English language articles by searching MEDLINE (1966 to February 2005) and the 
bibliographies of the retrieved articles to examine the effect of soy protein supplementation 
on serum lipid levels in adults.  They found 41 randomized controlled trials in which isolated 
soy protein supplementation was the only intervention and assessed the net changes in serum 
lipids during intervention. Information on study design, sample size, participant 
characteristics, intervention, follow-up duration, and treatment outcomes was independently 
abstracted using a standardized protocol. Data from each study were pooled using a random-
effects model. They concluded soy protein supplementation was associated with a significant 
reduction in mean serum total cholesterol (−5.26 mg/dl), low-density lipoprotein cholesterol 
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(−4.25 mg/dl), and triglycerides (−6.26 mg/dl) and a significant increase in high-density 
lipoprotein cholesterol (0.77 mg/dl). At meantime, meta-regression analyses showed a dose-
response relation between soy protein and isoflavone supplementation and net changes in 
serum lipids.  
In conclusion, hypercholesterolemia is a major modifiable risk factor for 
cardiovascular disease. Most current studies have shown that intake of soy protein including 
isoflavones decreases total and low-density lipoprotein cholesterol and triglycerides and 
increases high-density lipoprotein cholesterol among adults with or without 
hypercholesterolemia. Replacing foods high in saturated fat and cholesterol with soy protein 
may have a beneficial effect on cardiovascular risk factors.    
 
b. Antioxidant activity in antiatherogenic effect of soy protein or soy 
isoflavone 
 
            Oxidative processes are thought to be important in the initiation and progression of 
atherosclerosis. The oxidation hypothesis of atherosclerosis is based on the oxidative 
modification of LDL and phospholipids, which leads to foam cell formation and proliferation, 
which create an inflammatory state. Prevention of lipid oxidation and, specifically, LDL 
oxidation is thought to be potentially important for the prevention of atherosclerosis and 
ischemic heart disease (Gutteridge et al. 1993).  Current thinking is that antioxidants inhibit 
lipid peroxidation and, thus, protect against CVD. Many reactive species such as reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) are formed from physiological 
processes in the body, which contribute to aging, mutagenesis, carcinogenesis, DNA damage, 
and cardiovascular disease (Croft, 1998). Dietary isoflavones are also thought to protect 
against cardiovascular disease by the antioxidant properties which have been one important 
focus of particular. Potential mechanisms by which soy isoflavones might prevent 
atherosclerosis include a beneficial effect on these antioxidant effects, either in 
antiatherogenic effect of soy protein with intact isoflavones, or the effects of isoflavones 
without soy protein (Diaz et al. 1997). Yamakoshi et al. (2000) investigated the 
antiatherogenic effects of isoflavones (containing 429.4 mg/g isoflavone aglycones) without 
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soy protein from fermented soy in cholesterol-fed rabbits.  The atherosclerotic lesion area of 
the aortic arch was significantly lower in the isoflavone fed groups than in the cholesterol fed 
control group. They suggested that the antioxidative action of isoflavones inhibited the 
oxidation of LDL because immunohistochemical analysis showed fewer oxidized LDL-
positive macrophage-derived foam cells in atherosclerotic lesions in the aortic arch of 
isoflavone groups. Also Mahn et al. (2005) suggested that a soy protein diet increased mRNA 
levels for the antioxidant genes cytochrome c oxidase and -glutamylcysteine synthetase 
(catalytic unit) in vasculature, resulting in reduced oxidative stress and increased nitric oxide 
bioavailability in an animal study. 
      Several authors have reported on in vivo and in vitro soy isoflavone studies for 
antioxidant activity (Jenkins et al. 2000; Hwang et al. 2003; Jiang et al. 2003; Yousef et al. 
2004; Park et al. 2005). Dietary isoflavones may confer significant health advantages 
including cholesterol reduction, antioxidant activity, and possibly a reduced cancer risk. 
However, the concern has also been raised that phytoestrogens may be endocrine disrupters 
and major health hazards. Jenkins et al. (2000) assessed the effects of soy protein as a rich 
source of isoflavonoid phytoestrogens on LDL oxidation and sex hormone receptor activity. 
Thirty-one hyperlipidemic subjects underwent two 1-month low-fat metabolic diets in a 
randomized crossover study. The major differences between the test and control diets were 
an increase in soy protein foods (33 g/d soy protein) providing 86 mg isoflavones/d. No 
significant difference was detected in ex vivo sex hormone activity between urine samples 
from the test and control periods. Soy consumption did not increase the risk for hormone-
dependent cancers. However, in this study, the main point was that the test diet decreased 
both oxidized LDL measured as conjugated dienes in the LDL fraction and the ratio of 
conjugated dienes to LDL cholesterol. In conclusion, consumption of high-isoflavone foods 
was associated with reduced levels of circulating oxidized LDL which may become a 
cardiovascular disease risk and mediate the development of atherosclerosis by inflammatory 
processes.  
 Hwang et al. (2003) indicated the inhibition of superoxide radical (O2−•) production 
and enhanced levels of free nitric oxide (NO) prevented LDL modification in an equol 
pretreatment of J774 monocyte/macrophages culture, apparently via the inactivation of the 
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reduced nicotinamide adenine dinucleotide phosphate oxidase complex.  Conversely, 
inhibition of NO production enhanced LDL oxidative modification; and the combination of 
reduced NO and increased O2−• production yielded maximum LDL formation (Hwang et al. 
2003).  
        Jiang et al. (2003) also investigated the effects of bioactive isoflavone 
metabolites on hyperlipidemia, endothelial dysfunction and the development of 
atherosclerotic lesions in apolipoprotein E-deficient (apoE (0)) mice fed a Western high-fat 
diet. Supplementation with dihydrodaidzein (DiD), dehydroequol (DeE) (both 25 mg kg (-1) 
x day (-1)) and their combination (D/D; 12.5 mg kg(-1) x day(-1) for each) for 24 weeks 
reduced plasma high-density lipoprotein (HDL) and non-HDL cholesterol. D/D also reduced 
the triglyceride level. In the abdominal aorta of apoE(0) mice, these compounds significantly 
increased endothelial nitric oxide (NO)-mediated vasorelaxations induced by acetylcholine, 
but had a minor effect on relaxations induced by the NO donor S-nitroso-N-
acetylpenicillamine. Isoflavone treatment for 24 weeks had no effect on the total area of 
atherosclerotic plaques in the whole aorta. However, DeE reduced the plaque thickness in the 
aortic arch by 29%, although this did not reach statistical significance. The endothelial 
dysfunction in apoE (0) mice was associated with hyperlipidemia and increased vascular 
oxidative stress measured as increased superoxide production. Both isoflavones have 
superoxide-scavenging activities in vitro. They suggested that chronic supplementation with 
bioactive isoflavone metabolites may protect endothelial NO function in apoE(0) mice, 
through both lipid-lowering and antioxidant actions.  
        Yousef et al. (2004) investigated the effects of either 2.5 or 5 mg/kg B.W. doses 
of isoflavones on the levels of free radicals in male New Zealand White rabbits. Treatment 
with isoflavones caused significant (P<0.05) decrease in the concentrations of free radicals in 
plasma, liver, brain and kidney by two doses, respectively, as compared to the control. On the 
other hand, the activity of glutathione S-transferase (GST) did not change in treated animals 
as compared to control. However, Mahn et al. (2005) showed mitochondrial levels of 
glutathione (GSH) were significantly higher feeding of rats with a soy protein-rich diet 
during gestation and adult life, suggesting that production of reactive oxygen species (ROS) 
was decreased. Furthermore, in Mahn et al. (2005) study, increased antioxidant enzymes 
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manganese superoxide dismutase and cytochrome c oxidase in aortic tissue were also 2- to 3-
fold higher feeding the soy protein-rich diet.    
        In a spontaneously hypertensive rat (SHR) study, investigator aimed the 
protective effect of isoflavone against hypertension. Both the mitigation of oxidative stress 
and prevention of nitric oxide (NO, a potent vasodilator) were reported. Park et al. (2005) fed 
the 8 wk-old male SHR with a casein-based high fat diet (120 g fat, 1 g cholesterol/kg diet) 
for 30 d, either with or without 10 g of soy powder (containing 31.2% of isoflavones)/kg. 
During the 30-d study period, tail systolic blood pressures (BP) in the control SHR group 
increased, while the isoflavone-supplemented group benefited from a clear antihypertensive 
effect. The serum NO and total radical trapping antioxidant potential (TRAP) were elevated 
in the isoflavone group. The isoflavone group also experienced a significant decrease in 
oxidative DNA damage in leukocytes, using comet assay. DNA damage correlated positively 
with incremental BP during the study, and systolic BP at the end of the study. They indicated 
that soy isoflavone has an antihypertensive effect, possibly through the amelioration of 
oxidative stress, and the augmentation of NO production in SHR.  
         On the other hand, atherogenesis is also a complex process, including 
infections, inflammation, and autoimmunity (Leinonen et al. 2002). Heat shock proteins 
(HSP) were identified as possible autoantigenic determinants acting as immune targets in the 
atherosclerotic process (Pockley et al. 2002). In a previous study, the increase of *NO 
production may enhance HSP expression in some cell types (Hirvonen et al. 1996). Soy 
isoflavones may affect several biochemical pathways both the synthesis of nitric oxide (NO) 
and heat shock proteins (HSP) that are important factors for atherosclerosis development. 
More recently, Rosier et al. (2006) investigated the influence of soy isoflavones on NO 
production and HSP in experimental atherosclerosis in New Zealand rabbits with casein and 
soy isoflavones (5 mg/kg/day) (ISO). The ISO group showed the concentration of (*) NO 
metabolites (NO x)( *NO production) in plasma and the levels of reactive antibodies to HSP 
in aortic tissue were significantly decreased, as well as, a significant reduction of cholesterol 
in LDL and in aorta compared with the CAS group.        
       As a general conclusion from these studies, decreasing  in the concentrations of 
oxidized LDL and free radicals and superoxide radical production in plasma, and enhancing 
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endothelial nitric oxide synthase and the antioxidant enzymes manganese superoxide 
dismutase and cytochrome c oxidase and total radical trapping antioxidant potential (TRAP) 
are the main issues in isoflavone antioxidant properties.         
 
c. Effects of soy isoflavones on blood pressure    
         
      Washburn et al. (1999) and Teede et al. (2001) found that soy protein 
supplementation significantly reduced blood pressure in men and perimenopausal or 
postmenopausal women. Nevala et al. (2000) found that a soy-based diet attenuated the 
development of hypertension in spontaneously hypertensive rats. In contrast with the above 
studies, Hodgson et al. (1999) reported that soy isoflavonoids do not reduce blood pressure in 
hypertensive humans. Therefore, Rivas et al. (2002) conducted a randomized, double-blind 
comparative study of soy milk vs. cow’s milk in people with mild-to-moderate hypertension 
to corroborate the effects of soy isoflavone on blood pressure.   
      Washburn et al. (1999) investigated the effect of soy protein supplementation with 
known levels of phytoestrogens on cardiovascular disease risk factors and menopausal 
symptoms in 51 perimenopausal women in a randomized, double-blind crossover trial for 6-
week periods. Women were randomly assigned to one of the three diets: 20 g of complex 
carbohydrates (comparison diet), 20 g of soy protein containing 34 mg of phytoestrogens 
given in a single dose, and 20 g of soy protein containing 34 mg of phytoestrogens split into 
two doses. A significant decline in diastolic blood pressure (5 mm Hg lower) was noted in 
the twice-daily soy diet, compared with the placebo diet. Significant declines in total 
cholesterol (6% lower) and low density lipoprotein cholesterol (7% lower) were observed in 
both soy diets compared with the placebo diet. Although nonsignificant effects were noted 
for a number of measures of quality of life, a significant improvement was observed for the 
severity of vasomotor symptoms and for hypoestrogenic symptoms in the twice-daily group 
compared with the placebo group. Soy supplementation in the diet of 
nonhypercholesterolemic, nonhypertensive, perimenopausal women resulted in significant 
improvements in lipid and lipoprotein levels, blood pressure, and perceived severity of 
vasomotor symptoms. These data confirmed the potential importance of soy supplementation 
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in reducing chronic disease risk in Western populations. Also, Teede et al. (2001) performed 
soy dietary containing phytoestrogens (40 g soy protein, 118 mg isoflavones) to measure 
blood pressure (BP), lipids, vascular function (systemic arterial compliance and pulse wave 
velocity), and endothelial function (flow-mediated   vasodilation) in a randomized, double-
blind trial in two hundred thirteen healthy subjects (108 men and 105 postmenopausal 
women) for 3 months. Although, in this study, Teede et al. (2001) did not show improved 
vascular function after soy intervention compared with casein placebo, urinary 
phytoestrogens increased, accompanied by a significant fall in BP reflected in systolic, 
diastolic, and mean BP. In the lipid model, soy induced greater changes, compared with 
placebo. On individual analysis, significant contributors included a reduction in the low- to 
high-density lipoprotein ratio and triglycerides and peripheral PWV (reflecting peripheral 
vascular resistance) improved with soy, whereas flow-mediated vasodilation (reflecting 
endothelial function) declined (in males only), compared with casein placebo. In 
normotensive men and postmenopausal women, soy improved BP and lipids. On the other 
hand, Hodgson et al. (1999) indicated that soy isoflavonoids do not reduce blood pressure in 
hypertensive humans. These different results may be induced by different subjects. Fifty-nine 
subjects with high-normal range systolic BP completed a randomized, double blind, placebo-
controlled trial of two-way parallel design and 8 weeks duration to assess the effect of 
isoflavonoid supplementation on BP. One tablet containing 55 mg of isoflavonoids, including 
30 mg of genistein, 16 mg of biochanin A (a genistein precursor), 1 mg of daidzein, and 8 mg 
of formononetin (a daidzein precursor), or one placebo tablet, was taken daily with the 
evening meal. Significant increases in urinary excretion of genistein and daidzein were 
observed in the group taking the isoflavonoid supplement. BP was measured at two visits, 
and ambulatory BP monitoring was performed over one 24-h period, at baseline and 
postintervention. There was no significant difference between groups, after adjustment for 
baseline values, in postintervention supine BP, erect BP, or 24-h ambulatory BP. Adjustment 
for age, sex and weight change did not alter the result. Therefore, these results do not support 
the hypothesis that isoflavonoids, and genistein in particular, are major contributors to the BP 
lowering effect of vegetarian diets. Subsequently, Rivas et al. (2002) also conducted the soy-
based diets study in 40 men and women with mild-to-moderate hypertension. In this study, 
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the antihypertensive potential of soy milk (500 mL twice daily) compared with cow’s milk 
was investigated in a 3-mo double-blind randomized trial. Before initiation of the study, 
urinary isoflavonoids (measured by HPLC) were undetectable in most cases. After 3 mo of 
soy milk consumption, systolic blood pressure decreased by 18.4 ± 10.7 mmHg compared 
with 1.4 ± 7.2 mmHg in the cow’s milk group (P < 0.0001), diastolic blood pressure 
decreased by 15.9 ± 9.8 mmHg vs. 3.7 ± 5.0 mmHg in the cow’s milk group (P < 0.0001) and 
mean blood pressure decreased by 16.7 ± 9.0 mmHg compared with 3.0 ± 4.6 mmHg in the 
cow’s milk group (PP < 0.0001). Urinary genistein was strongly (r = -0.588) and significantly 
(P = 0.002) correlated with the decrease in blood pressure, particularly for diastolic values. 
Chronic soy milk consumption had modest, but significant hypotensive action in essential 
hypertensive subjects. This hypotensive action was correlated with the urinary excretion of 
the isoflavonoid genistein. 
In summary, the effect of soy isoflavone on blood pressure is also controversial, 
maybe due to the subjects’ basal level of blood pressure, age, diet and isoflavone dosages. 
Some current research focuses on soy protein supplementation in perimenopausal or 
postmenopausal women and devised animal hypertension models. The apparent decreased 
blood pressure is evident. However, in this research field, they also did not try to control the 
relationship between interindividual variability in isoflavone bioavailability and blood 
pressure levels.    
   
d. Insulin sensitivity and Cardiovascular Risk 
 
      The metabolic syndrome (MS) which includes hypertension, dyslipidemia, 
increased prothrombic state, and central obesity may precede development of Type 2 
diabetes mellitus (DM) and cardiovascular disease (Reaven et al. 2004). The primary factor 
underlying progression of MS is development of insulin resistance and hyperinsulinemia 
(Reaven et al. 2004). To investigate the effects of soybean protein on glucose tolerance and 
insulin receptor gene expression, Iritani et al. (1997) fed Wistar fatty rats (genetically obese, 
noninsulin-dependent diabetes mellitus) and their lean littermates (8 wk old) using a casein or 
soybean protein diet containing 9% partially saturated beef tallow (plus 1% corn oil), 10% 
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corn oil or 10% fish oil for 3 wk. In glucose tolerance tests, plasma insulin concentrations 
were significantly higher in obese rats fed corn oil or fish oil than in those fed partially 
saturated beef tallow, particularly in the soybean protein groups. Although, plasma glucose 
concentrations were not significantly affected by dietary protein or fat, soy protein-fed rats 
had lower fasting plasma glucose compared with casein-fed animals in Lavigne et al. (2000) 
study. Iritani et al. (1997) also reported the insulin receptor mRNA concentrations in livers 
and adipose tissues were higher in rats fed soybean protein/partially saturated beef tallow 
than in those fed any other protein/fat combination. Dietary soybean protein may help to 
reduce the insulin resistance, but only when a diet low in polyunsaturated fatty acids is 
consumed. On the other hand, the insulin receptor mRNA concentrations in adipose tissue 
were generally lower in the obese rats of all dietary groups than in the lean rats, suggesting 
that insulin resistance may be due to a defect of insulin receptor gene expression.  
        Lavigne et al. (2000) also determined the effects of feeding various dietary 
proteins on insulin sensitivity and glucose tolerance in rats. They fed male Wistar rats for 
28 days with isoenergetic diets containing either casein, or soy protein, or cod protein. Cod 
protein-fed and soy protein-fed rats had lower insulin concentrations compared with casein-
fed animals. After intravenous glucose bolus, cod protein- and soy protein-fed rats induced 
lower incremental areas under glucose curves compared with casein-fed animals. Improved 
peripheral insulin sensitivity was confirmed by higher glucose disposal rates in cod protein- 
and soy protein-fed rats compared with casein-fed animals. Moreover, test meal experiments 
revealed the lower plasma insulin concentrations in cod protein- and soy protein-fed animals 
could be also due to decreased pancreatic insulin release and increased hepatic insulin 
removal. They concluded the metabolic responses to three common dietary proteins indicate 
that cod and soy proteins, when compared with casein, improve fasting glucose tolerance and 
peripheral insulin sensitivity in rats.  
         Futhermore, Davis et al. (2005) focused on physiological effects of soy-based 
diets with varying isoflavone content on pathogenesis of insulin-resistance and 
cardiovascular risk using a rodent model that reflects early stages of insulin resistance and 
MS. In this study, lean male SHHF (+/cp) rats were randomly assigned to the several 
treatment groups: casein (control, C); low-isoflavone (LIS) soy protein isolate; high-
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isoflavone (HIS) soy protein isolate; or C+ 0.01 % rosiglitazone (CR) for thirty-six weeks. 
Liver weight, heart weight, total plasma cholesterol, fasting blood glucose were lower in soy-
fed animals compared to control. Body weight, kidney weight, alanine aminotransferase 
(ALT), fasting plasma insulin, and homeostasis model assessment (HOMA) score were also 
lower in LIS-fed rodents compared to casein treatment. All diet groups exhibited lower urine 
protein and small arteriole content compared to controls.    
  In conclusion, insulin sensitivity related to CVD risk factors are also interested 
isoflavone studies recently. Concern regarding the safety and efficacy of isoflavones which 
necessitate discovering alternative therapies for prevention and treatment of insulin-
resistance still remains unknown. However, more research on interindividual variability in 
insulin resistance of isoflavone trials may help explain the importance of interindividual 
variability in isoflavone bioavailability.      
 
e. Effects of soy isoflavones on endothelial function  
                    
  The endothelium is crucial for the modulation of vessel tone and for the control of 
platelet adhesion and aggregation. Endothelial dysfunction, defined as an imbalance of 
endothelial-derived vasoactive factors leading to vasoconstriction and structural changes in 
the vessel wall, is an early event in the pathophysiology of atherosclerosis and hypertension, 
and it is an independent predictor of poor prognosis (Schachinger et al. 2000). Preliminary 
reports in female monkeys show enhancement of endothelium-dependent vasodilatation 
(Honoré et al. 1995). Soybeans contain a number of compounds that have weak estrogenic 
activity (Adlercreutz et al. 1995). Of these, the isoflavonoids are especially attractive, 
possessing antioxidant property (Jha et al. 1985) as well as the capacity to occupy estrogen 
receptors.  
   Some studies focused on the favorable effects on blood vessel function and 
improving vascular reactivity (Nestel et al. 1997; Walker et al. 2001; Yildirir et al. 2001; van 
der Schouw et al. 2002). Nestel et al. (1997) investigated a pure preparation of isoflavones 
from soybean on several important biomarkers of cardiovascular health in 21 menopause 
women. They found systemic arterial compliance was significantly improved in 
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perimenopausal and menopausal women taking soy isoflavones to about the same extent as is 
achieved with conventional hormone replacement therapy. These included systemic arterial 
compliance, a measure of elasticity of the major conduit arteries such as the aorta, the 
vasodilatory capacity of the microcirculation in the forearm, plasma lipid concentrations, and 
the oxidizability of LDL. The possibility that the heightened cardiovascular risk associated 
with the menopause, which is said to be ameliorated by soybeans, can be reduced with soy 
isoflavones was tested in a placebo-controlled crossover trial with 80-mg daily isoflavones 
(45 mg genistein) over 5- to 10-week periods. Although arterial pressure and plasma lipids 
and LDL oxidizability in vitro were unaffected, it believed that systemic arterial compliance 
(arterial elasticity) improved compared with placebo. The vasodilatory capacity of the 
microcirculation was measured in nine women; high acetylcholine-mediated dilation in the 
forearm vasculature was similar with active and placebo treatments. Also Walker et al. 
(2001) investigated whether genistein influences endothelium-dependent vasodilation in 
forearm vasculature of healthy human subjects and compared the effects of genistein with 
those of 17ß-estradiol. It is thought that genistein causes L-arginine/NO-dependent 
vasodilation in forearm vasculature of human subjects with similar potency to 17ß-estradiol 
and potentiates endothelium-dependent vasodilation to acetylcholine. In this study, forearm 
blood flow responses were measured with strain-gauge plethysmography. Genistein (10 to 
300nmol/min, each dose for 6 minutes) significantly increased a dose-dependent increase in 
forearm blood flow. Daidzein, another phytoestrogen, was ineffective, but equimolar 
concentrations of 17ß-estradiol caused similar vasodilation to genistein. Responses to 
genistein and 17ß-estradiol were inhibited to the same degree by the NO synthase inhibitor 
NG-monomethyl-L-arginine. A threshold dose of genistein potentiated the endothelium-
dependent vasodilator acetylcholine. Furthermore, Yildirir et al. (2001) investigated the 
effects of soy protein diet on endothelial function and plasma lipids parameters assessed by 
two different methods in twenty hypercholesterolemic, nonsmoker male patients with a 
normal body mass index. They showed soy protein diet significantly improves plasma lipid 
profile in patients with hypercholesterolemia. Furthermore, the endothelial function, as 
judged by two different methods (EDD and plasma TM levels), also improves with soy 
protein diet. After calculating their daily requirements, a diet with 25-30% of energy from 
 
 
 
26
fats. 10-12% from proteins and the rest from carbohydrates were instituted. Sixty percent of 
the animal source proteins of the diet were substituted by soy. The anthropometric measures, 
lipid parameters, and endothelial functions of the subjects were assessed at baseline and 6 
weeks after soy protein diet. Flow-mediated endothelium-dependent dilatation (EDD) and 
plasma thrombomodulin (TM) levels were evaluated as endothelial function parameters. The 
mean plasma TM levels were also significantly reduced with diet. Studies of the brachial 
artery indicated a borderline dilatation in baseline brachial artery diameter, however the 
diameter at reactive hyperemia was significantly larger after diet, resulting in a significant 
improvement of EDD. After soy protein substitution, plasma total cholesterol, low-density 
lipoprotein cholesterol, apolipoprotein B, and triglyceride levels decreased significantly 
compared to animal protein-based diet. On the other hand, van der Schouw et al. (2002) have 
focused the effect of Western dietary phytoestrogen intake on the risk of atherosclerosis and 
arterial degeneration through an effect on arterial walls, especially among older women. Four 
hundred three women with natural menopause either between 1987 and 1989 or between 
1969 and 1979 were selected from the baseline data of the PROSPECT study (n=17 395). 
Isoflavone and lignan intake was calculated from a food-frequency questionnaire. Aortic 
stiffness was noninvasively assessed by pulse-wave velocity measurement of the aorta. After 
adjustment for age, body mass index, smoking, physical activity, mean arterial pressure, 
follow-up time, energy intake, dietary fiber intake, glucose, and high density lipoprotein 
cholesterol, increasing dietary isoflavone intake was associated with decreased aortic 
stiffness. Increasing dietary intake of lignans was also associated with decreased aortic pulse-
wave velocity.  
      Squadrito et al. (2003) also evaluated genistein effects on endothelial function in 
79 healthy postmenopausal women using a double-blind, controlled, randomized design. 
Subjects randomly were assigned to receive continuous estrogen/progestin therapy (n = 26; 
17β-estradiol [1 mg/d] combined with norethisterone acetate [0.5 mg/d]), genistein (n = 27; 
54 mg/d), or placebo (n = 26). Brachial artery flow–mediated, endothelium-dependent 
vasodilation and plasma levels of nitrites/nitrates (a marker of nitric oxide metabolism) and 
endothelin-1 were measured at baseline and after 1 year of therapy. Treatment with genistein 
increased levels of nitrites/nitrates; estrogen/progestin therapy caused similar changes. 
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Plasma endothelin-1 levels decreased following 12 months of genistein and after 12 months 
of estrogen/progestin.Brachial artery flow–mediated dilation was improved by genistein and 
by estrogen/progestin. There were no significant differences between estrogen and genistein 
for any of these parameters.    
      Colacurci et al. (2005) evaluated the effects of soy isoflavone administration on 
endothelial function in healthy sixty postmenopausal women assigned to receive isoflavone 
or placebo tablets for 6 months. Endothelium-dependent vasodilatation was measured by 
brachial reactivity technique along with levels of plasma soluble intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin. Differences 
between endothelium-dependent and endothelium-independent vasodilatation were assessed 
by evaluating brachial reactivity parameters after reactive hyperemia and after sublingual 
administration of nitroglycerin; furthermore, in the active group, the effect of isoflavones was 
also evaluated during the intra-arterial infusion of N-monomethyl-L-arginine. Serum levels 
of lipids [high-density lipoprotein and low-density lipoprotein cholesterol, triglycerides and 
lipoprotein (a)] and hemostatic factors (prothrombin, fibrinogen, plasminogen activator 
inhibitor-1, and fibrin D-dimer) were also measured. Isoflavone treatment versus placebo 
was associated with a significant improvement in endothelium-dependent vasodilatation. 
Intra-arterial infusion of N-monomethyl-L-arginine inhibited the significant effect of 
isoflavones on endothelium-mediated vasodilatation. Furthermore, isoflavone group 
experienced statistically significant reductions in plasma concentrations of ICAM-1, VCAM-
1, and E-selectin. These findings suggest a positive influence of soy isoflavones on 
endothelial function in healthy postmenopausal women as evidenced by an improvement in 
endothelium-dependent vasodilatation and a reduction in plasma adhesion molecule levels.  
 In conclusion, isoflavone may cause several alterations in vasoactive factors 
characteristic of endothelial dysfunction including systemic arterial compliance, 
bioavailability of nitric oxide (NO), vasoconstrictor prostanoids, endothelin-1, E-selectin, 
ROS, ICAM-1, VCAM-1. But interindividual variability in isoflavone bioavailability might 
influence such findings.   
 
f. Homocysteine and the risk of vascular disease 
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     Several studies have shown elevated homocysteine levels in patients with 
coronary, cerebrovascular, or peripheral arterial diseases; this association is frequent and 
independent of most other risk factors for atherosclerosis (Malinow et al. 1994). Suggested 
mechanisms include a direct effect on the vascular endothelium (Tsai et al. 1994) and a role 
in enhancing the risk of thrombosis (Fryer et al. 1993). 
      Hermansen et al. (2001) evaluated if a dietary supplement of soy protein, 
isoflavones, and cotyledon fiber (Abalon) affects cardiovascular risk markers in type 2 
diabetic subjects. Twenty type 2 diabetic subjects participated in a crossover trial. They were 
randomized to double-blind supplementation for 6 weeks with Abalon (soy protein [50 g/day] 
with high levels of isoflavones [minimum 165 mg/day] and cotyledon fiber [20 g/day]) or 
placebo (casein [50 g/day] and cellulose [20 g/day]), separated by a 3-week wash-out period. 
This study demonstrated significantly lower mean values after Abalon intake than after 
placebo treatment for LDL cholesterol, LDL/HDL ratio, triglycerides, and homocysteine.  
       Also, Jenkins et al. (2002) investigated the effects of high- and low-isoflavone 
soy-protein foods on both lipid and nonlipid risk factors for coronary artery disease (CAD) in 
forty-one hyperlipidemic men and postmenopausal women. Three 1-mo diets: a low-fat dairy 
food control diet and high- (50 g soy protein and 73 mg isoflavones daily) and low- (52 g soy 
protein and 10 mg isoflavones daily) isoflavone soyfood diets were chosen in this study. 
Fasting blood samples were drawn and blood pressure was measured at the start and end of 
each diet. Compared with the control diet, both soy diets resulted in significantly lower total 
cholesterol, and ratios of total to HDL cholesterol, LDL to HDL cholesterol, and estimated 
CAD risk including reductions in oxidized LDL, homocysteine, and blood pressure.  
    Nagata et al. (2003) examined a cross-sectional relationship between soy product 
intake and serum homocysteine level in 201 premenopausal Japanese women. Intakes of soy 
products, folate, methionine and vitamins B-6 and B-12 were estimated by a semiquantitative 
food frequency questionnaire. Folate status was also assessed by measuring serum folate. Soy 
product intake in terms of soy protein as well as soy isoflavone intake was modestly but 
significantly inversely associated with serum homocysteine level after controlling for 
covariates. Soy product intake was also significantly positively correlated with serum folate. 
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Although it is unclear the extent to which each component of soy, such as folate and 
isoflavones, is associated with the serum homocysteine concentration, this biochemical 
complex appears to have a favorable effect on homocysteine metabolism in premenopausal 
women.    
  In conclusion, homocysteine levels related to CVD risk factors are also of recent 
interest with respect to isoflavone. However, more research on interindividual variability in 
homocysteine levels of duing isoflavone trials may be helpful.   
 
g. Atherosclerotic thrombus or plaques formation and the risk of vascular 
disease 
 
     To address its effects on clinical cardiovascular endpoints such as incidence of 
coronary heart disease or atherosclerosis progression in animal or human subjects, some 
studies focused on the effects of soy consumption on indices of endothelium-dependent and 
endothelium-independent vascular reactivity in men. A randomized, double-blind trial 
demonstrated a decline in flow-mediated (endothelium-dependent) peripheral vasodilatory 
function in healthy men who had consumed isoflavone-containing soy protein supplements 
for 3 mo compared with men who had consumed a casein placebo (Teede et al. 2001). Also, 
a previous study found a tendency toward a decline in endothelium-dependent vasodilatory 
function of coronary arteries in male monkeys fed isoflavone-replete soy protein for 6 mo 
compared with monkeys fed isoflavone-deficient soy protein (Honoré et al. 1997). In contrast 
with the above studies, Lissin et al. (2004) reported these findings conflict with those from 
studies of women and female monkeys, in which isoflavone-containing soy supplements 
seemed to improve vascular reactivity.   
        Two studies with monkeys found an inhibitory effect of isoflavone-containing 
dietary soy protein on atherosclerosis in juvenile male and ovariectomized female monkeys, 
an effect that was partially lost when the isoflavones were removed from the soy protein by 
alcohol washing (Anthony et al. 1997; Wagner et al. 2003). Previously, Wilcox et al. 1995) 
reported genistein, an isoflavonoid derived from soy products, inhibited thrombin formation 
and platelet activation in vivo in addition to its antigrowth factor activity. This compound 
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had the potential to affect the progression of atherosclerotic disease by modifying 
coagulation responses. In this study, they did not establish its effect on experimental vascular 
lesion formation to assess the potential of genistein as a therapeutic for vascular disease. 
However, Raines et al. (1995) indicated that the increased levels of isoflavonoids, in 
particular genistein, which are associated with consumption of soy-based diets, inhibited cell 
adhesion, altered growth factor activity and inhibited cell proliferation involved in lesion 
formation. Furthermore, Adams et al. (2005) determined the effects of the long-term (31 mo) 
consumption of commercially available soy protein containing 2 concentrations of 
isoflavones on the development of atherosclerotic plaques and vascular reactivity in coronary 
arteries of adult male monkeys. The monkeys were fed atherogenic diets that differed only in 
the source of protein: Control (n = 30), casein and lactalbumin; low-isoflavone soy (n = 30), a 
mixture of unmodified soy protein isolate and isoflavone-depleted soy protein isolate 
containing 0.94 mg of isoflavones/g protein; and high-isoflavone soy (n = 31), unmodified 
soy protein isolate containing 1.88 mg of isoflavone/g protein. Although there were no effects 
of dietary soy on endothelium-dependent or -independent reactivity of coronary arteries, 
atherosclerosis (mean plaque size in the coronary arteries) was reduced by 34% in both 
groups fed soy protein. Plasma LDL cholesterol was reduced, whereas HDL cholesterol and 
apolipoprotein A-1 were increased in both groups that consumed soy protein.   
    In conclusion, potential factors by which soy isoflavones might prevent 
atherosclerosis include beneficial effects of soy and say isoflavones on serum lipid profiles. 
Isoflavones may decrease LDL-cholesterol levels and increase HDL-cholesterol levels and 
also have antioxidant properties which protect LDL from oxidation. These compounds also 
have some favorable effects on blood vessel function; lowering blood pressure; inhibiting 
thrombus formation; suppressing smooth muscle cell proliferation and migration and 
improving vascular reactivity. 
 
h. Cholesterol lowering mechanism of isoflavone 
    
 High total cholesterol and LDL cholesterol levels correlate with cardiovascular 
disease. Elevated cholesterol levels contribute to the formation of atherosclerotic plaques and 
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eventually to thrombosis or myocardial infarction (Anderson et al. 1995). The mechanism by 
which soy isoflavone exerts its effects is unknown and a matter of debate. But it is known 
that reduced LDL-cholesterol concentrations associated with estrogen intake are a direct 
result of increased LDL receptor activity (Kovanen et al. 1979). Although some studies 
reported that LDL receptor wasn’t required for the role of the atheroprotective action of soy 
isoflavones in prevention of cardiovascular disease for postmenopausal women (Adams et al. 
2002; Mortensen et al. 2004), recently, soy isoflavones were reported to affect sterol 
regulatory element binding proteins (SREBPs) and SREBP regulated genes related to LDL 
receptor expression in HepG2 cells (Mullen et al. 2004).  
     Baum et al. (1998) investigated the effect of soy protein and isoflavones on 
mononuclear cell LDL receptor messenger RNA (mRNA) in postmenopausal women over a 
6-mo feeding period to determine the possible role of isoflavones in lipid metabolism. Sixty-
six hypercholesterolemic, free- living, postmenopausal women were investigated in parallel-
group, double-blind trial with 3 interventions. After a control period of 14 d, all subjects were 
randomly assigned to 1 of 3 dietary groups (all with 40 g protein): a National Cholesterol 
Education Program (NCEP) Step 1 diet with protein from casein and nonfat dry milk 
(control), an NCEP Step 1 diet with protein from isolated soy protein containing moderate 
amounts of isoflavones (ISP56), or an NCEP Step 1 diet with protein from isolated soy 
protein containing high amounts of isoflavones (ISP90). Reverse transcription–polymerase 
chain reaction (RT-PCR) was used to quantitate LDL receptor mRNA concentrations. 
Mononuclear cell LDL receptor messenger RNA concentrations increased in subjects 
consuming ISP56 or ISP90 compared with the control (P < 0.05). Non-HDL cholesterol in 
both the ISP56 and ISP90 groups was reduced compared with the control group (P < 0.05). 
HDL cholesterol increased in both the ISP56 and ISP90 groups (P < 0.05), and the ratio of 
total to HDL cholesterol decreased significantly in both groups compared with the control (P 
< 0.05). This study indicated that soy protein, with different amounts of isoflavones, 
decreased the risk of cardiovascular disease via improved blood lipid profiles, and that the 
mechanism by which apolipoprotein B-containing lipoproteins were depressed may be via 
alterations in LDL receptor quantity or activity.  
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     Almost at the same time, two other authors (Kirk et al. 1998; Potter et al. 1998) 
also reported that isoflavones increased LDL receptor activity in C57BL/6 mice or 
postmenopausal women. Kirk et al. (1998) determined whether soy isoflavones had effect on 
cholesterol levels or on susceptibility of LDL to oxidative modification in LDLR-null mice 
and whether dietary isoflavones conferred protection against atherosclerosis in mice. 
C57BL/6 and LDL receptor-deficient (LDLR-null) mice were fed soy protein-based, high fat 
diets with high isoflavones (IF+) or diets from which isoflavones had been extracted (IF ). 
Because LDLR-null mice develop extensive  atherosclerosis and hypercholesterolemia after 
minimal time on a high fat diet, they were fed the diets for 6 wk, whereas C57BL/6 mice 
were fed the diets for 10 wk. Plasma cholesterol levels did not differ between LDLR-null 
mice fed IF  and those fed IF+, but were 30% lower in C57BL/6 mice fed the IF+ diet than 
in those fed the IF  diet. Susceptibility of LDL to oxidative modification, measured as the 
lag phase of conjugated diene formation in LDLR-null mice, was not altered by isoflavone 
consumption. All LDLR-null mice developed atherosclerosis, and the presence or deficiency 
of dietary isoflavones did not influence atherosclerotic lesion area. In contrast, atherosclerotic 
lesion area was significantly reduced in C57BL/6 mice fed IF+ compared with those fed IF . 
Thus, these findings suggest that soy isoflavones might lower cholesterol levels by increasing 
LDL receptor activity, and the reduction in cholesterol may offer some protection against 
atherosclerosis. Potter et al. (1998) investigated in 66 free-living, hypercholesterolemic, 
postmenopausal women during a 6-mo, parallel-group, double-blind trial with 3 interventions 
to determine effects of soy protein (40 g/d) containing moderate and higher concentrations of 
isoflavones on blood lipid profiles, mononuclear cell LDL receptor messenger RNA, and 
bone mineral density and content.   All subjects were randomly assigned to 1 of 3 dietary 
groups: Step I diet with 40 g protein/d obtained from casein and nonfat dry milk (CNFDM), 
Step I diet with 40 g protein/d from isolated soy protein containing 1.39 mg isoflavones/g 
protein (ISP56), or Step I diet with 40 g protein/d from isolated soy protein containing 2.25 
mg isoflavones/g protein (ISP90). Mononuclear cell LDL receptor mRNA was increased in 
subjects consuming ISP56 or ISP90 compared with those consuming CNFDM (P < 0.05). 
Total and regional bone mineral content and density were assessed. Non-HDL cholesterol for 
both ISP56 and ISP90 groups was reduced compared with the CNFDM group (P < 0.05). 
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HDL cholesterol increased in both ISP56 and ISP90 groups (P < 0.05). Significant increases 
occurred in both bone mineral content and density in the lumbar spine. Intake of soy protein 
at both isoflavone concentrations for 6 mo may decrease the risk factors associated with 
cardiovascular disease in postmenopausal women.  
   Furthermore, soy isoflavones were reported to affect sterol regulatory element 
binding proteins (SREBPs) and SREBP regulated genes related to LDL receptor expression 
in HepG2 cells (Mullen et al. 2004). These genes regulated by the SREBPs include LDL 
receptor (Tontonoz et al. 1993), HMG CoA reductase (Millinder-Vallett et al. 1996), 3-
hydroxy-3-methylglutaryl coenzyme A (HMG CoA) synthase (Dooley et al. 1999) and fatty 
acid synthase (Magana et al. 2000). SREBP-2 is encoded on by its own gene and is primarily 
responsible for the regulation of genes involved in cholesterol biosynthesis and metabolism 
(Hua et al. 1993). Because SREBPs are critical for the regulation of intracellular sterol and 
lipid homoeostasis, Mullen et al. (2004) examined the effects of isoflavone-containing soy 
extract and individual isoflavones on SREBP levels and maturation as well as their effects on 
the SRE-regulated genes HMG CoA synthase, HMG CoA reductase, and the LDL receptor. 
Understanding the metabolic effects of the various components of soy is an important goal to 
help guide or design the modification of cholesterol-lowering soyfoods or dietary 
supplements.   
     Mullen et al. (2004) proposed that the isoflavone component of soy mediates this 
effect, at least in part, by affecting cellular sterol homeostasis. They investigated the effects 
of an isoflavone-containing soy extract and the individual isoflavones on the maturation of 
the sterol regulatory element binding proteins (SREBP) and the expression of SRE-regulated 
genes controlling lipid metabolism and found a corresponding increase in the mature form of 
SREBP-2 in both soy extract– and isoflavone-treated human hepatoma cell line (HepG2). 3-
Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase protein and HMG CoA 
synthase mRNA levels also increased. When HepG2 cells were transiently transfected with 
HMG CoA synthase and LDL receptor reporter plasmids there was an increase in expression 
in response to soy extract or isoflavone treatment from both of these promoters. The 
mechanism responsible for this effect may be via a statin-like inhibition of HMG CoA 
reductase enzyme activity or by enhanced SREBP processing via the SREBP cleavage 
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activating protein. They concluded that maturation of SREBP and induction of SRE-
regulated genes produced an increase in surface LDL receptor expression that increased the 
clearance of plasma cholesterol, thus decreasing plasma cholesterol levels.    
     Another topic about the mechanism for the cholesterol lowering ability of soy 
protein and isoflavone was reported the peroxisome proliferator activator receptor (PPAR) -
dependent and –independent pathways. Recent evidence suggests that isoflavones along with 
other botanical compounds may be agonists or activators of the "promiscuous" nuclear 
receptors regulating cellular lipid metabolism, most notably the PPARs (Mezei et al. 2003; 
Kim et al. 2004). The three different isoforms of PPARs ( , , and ) have overlapping tissue 
distributions and functions associated with lipid metabolism. Results of in vitro studies 
demonstrate that the soy isoflavones, particularly genistein and daidzein, were able to activate 
both PPAR - and PPAR -mediated gene expressions (Mezei et al. 2003). The soy isoflavone 
genistein has been identified as a ligand of the PPAR  receptor (Dang et al. 2003). Gene 
profiling suggests that genistein is regulating gene expression through PPAR , which acts to 
stimulate mitochondrial fatty acid oxidation (Kim et al. 2004). Recently, Mezei et al. (2006) 
reported that dietary isoflavone supplementation modulated lipid metabolism via PPAR -
dependent and -independent mechanisms. In this study, both male and female mice were 
studied to determine whether the estrogen receptor and high circulating estrogen levels would 
be sufficient to produce changes in lipid levels associated with isoflavone consumption. 
Alternately, changes in lipid levels might be independent of sex, or there may be an 
interaction between sex and the presence of the PPAR  receptor.   
       In the study by Mezei et al. (2006), male and female 129/Sv mice were obtained, 
including both wild-type and genetically altered PPAR  knockout mice. Groups of mice were 
fed high-fat atherogenic diets containing soy protein +/- isoflavones and PPAR  agonist 
fenofibrate for 6 wk. At the end of 6 wk, serum and tissue lipid levels were measured along 
with hepatic gene expression. Most notably, serum triglycerides were reduced by isoflavone 
consumption. Compared with intake of a low-isoflavone basal diet, isoflavone intake reduced 
serum triglyceride levels by 36 and 52% in female and male wild-type mice, respectively, 
compared with 55 and 52% in fenofibrate-treated mice. The wild-type mice contributed to 
reduced serum triglyceride levels due to isoflavone intake. And loss of the PPAR  receptor in 
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soy isoflavone fed mice decreased less serum triglyceride levels than wild-type mice. 
However,  soy isoflavones also improved serum triglyceride levels in knockout mice because 
female and male PPAR  –/– mice showed reductions in serum triglyceride in the  soy 
isoflavone fed group, whereas fenofibrate did not, suggesting that two different regulatory 
mechanisms may be affected by isoflavone intake. Thus there was a positive effect of 
isoflavone intake on serum triglyceride levels in the absence of PPAR . Isoflavone intake 
resembled action of fenofibrate on PPAR -regulated gene expression, although less robustly 
compared with fenofibrate. They suggested that, at the levels consumed in this study, 
isoflavone intake was altering lipid metabolism in a manner consistent with activation of 
PPAR  and also via a PPAR -independent mechanism as well. 
In conclusion, the mechanism for the cholesterol lowering ability of soy protein and 
isoflavone is the topic of many hypotheses. Although the mechanism by which isoflavone 
alters plasma lipoprotein concentrations is still a matter of debate, besides increase in hepatic 
LDL-receptor activity, change in hepatic biotransformation of cholesterol and decreasing 
intestinal absorption of cholesterol might be factors. We now have much more interesting 
progress in this field including effects of isoflavones on sterol regulatory element binding 
proteins (SREBPs), SREBP regulated genes related to LDL receptor expression and the 
peroxisome proliferator activator receptor (PPAR) -dependent and –independent pathways.            
 
D. Saponins and lessening of plasma cholesterol   
 
                  Saponins, which are one kind of steroid or triterpene glucoside compounds 
associated with soy protein in addition to isoflavone, were also studied to see whether they 
had a cholesterol-lowering effect. Sugano et al. (1990) fed rat diets with the undigested high-
molecular-weight fraction of soybean protein (HMF) or soybean saponin diets also 
containing cholesterol (0.5%) and sodium cholate (0.125%). Soybean saponin equaled to that 
contained in HMF, which can significantly decrease serum cholesterol levels, did not lower 
serum cholesterol. Only the addition of 1.3% of saponin to the soy protein diet decreased 
serum cholesterol level. Yamakoshi et al. (2000) showed that saponin-rich extract diets 
containing 1% cholesterol with 1.09% saponin did not affect the serum lipid profile in 12 -
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wk-old New Zealand white male rabbits compared to controls which did not consume 
cholesterol, isoflavone or saponins. 
                  On the other hand, several studies on the effect of saponins on improving lipid 
profiles have also been reported. To investigate the potency of saponin with respect to its 
hypoglycaemic and hypolipidaemic action, and the association of these effects with oxidative 
stress, Rodrigues et al. (2005) used two groups ( n =6): control group and saponin-treated 
group (60 mg/kg) during 30 days in male Wistar rats. They reported saponin-treated animals 
had increased low-density lipoprotein-cholesterol/triacylglycerol ratio and decreased 
triacylglycerol, very low-density lipoprotein-cholesterol and total/high-density lipoprotein-
cholesterol ratio than the control group. Saponin-treated rats showed lower lipid 
hydroperoxide than control rats, indicating decreased potential to atherosclerosis. No 
alterations were observed in antioxidant enzymes, superoxide dismutase and glutathione 
peroxidase, while lipid hydroperoxide were decreased in saponin-treated rats. They 
concluded the beneficial effects of saponin on serum lipids were related to a direct saponin 
antioxidant activity.  
             Furthermore, Lee et al. (2005) showed that a diet containing 2.2 mmol/kg group B 
soyasaponins caused significantly lower plasma total cholesterol and non-HDL cholesterol 
(by 20 and 33%) in ten 11–12 wk old female golden Syrian hamsters compared with those 
fed casein. On the other hand, high and low producers of a putative saponin metabolite, 
divided by ranking peak area of this fecal metabolite, did not have significant differences in 
plasma total and non-HDL cholesterol, whereas high saponin metabolite producers had 
greater ratios of total cholesterol to HDL cholesterol compared with low producers. Thus, 
saponins which vary among soy protein sources were also modifiers of plasma lipids and 
may contribute to lessening of plasma cholesterol.     
 
E. Isoflavones and cancer 
 
      Among the numerous dietary factors, soy isoflavones have received much 
attention as nutritional components because of their inhibitory role in the growth of cancer 
cells in vitro and cancer development in vivo. The high level of soy isoflavones in Japanese 
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and Chinese diets and the low incidence of hormone-dependent neoplasm, including breast 
and prostate cancers, in these countries suggest a protective role of soy-derived substances 
against cancer (Adlercreutz et al. 1995; Hebert et al. 1998).  High consumption of soy milk 
has also been associated with reduced risk of prostate cancer (Jacobsen et al. 1998). The fact 
that soy isoflavone—particularly, genistein—can inhibit the carcinogenesis and the growth of 
cancers makes it a promising cancer preventive and/or therapeutic agent for various cancers. 
The inhibitory effects of soy isoflavones on cancer cell growth and the comprehensive view 
on molecular mechanism(s) for the role of isoflavone, particularly genistein, in cancer 
chemoprevention and/or treatment were summarized below.  
      Genistein, one of the predominant soy isoflavones, has been shown to compete 
with 17beta-estradiol for estrogen receptor binding because of its structural similarity. It 
causes inhibition of cell growth in breast and prostate cancers in vivo and in vitro. From gene 
expression profiles, genistein has been found to regulate the genes that are critical for the 
control of cell proliferation (Wei et al. 1995; Zhou et al. 1999), cell cycle (Davis et al. 1998), 
apoptosis (Lian et al. 1998), oncogenesis (Onozawa et al.1999), and cell signal transduction 
pathways. It has been reported that genistein induces apoptosis and inhibits activation of Akt 
signaling pathways (Li et al. 2002) and NF-kappaB (Li et al. 2005), both of which are known 
to maintain a balance between cell survival and apoptosis.  
           Wei et al. (1995) investigated the antiproliferative effects and antioxidant 
properties of the soybean isoflavone genistein in HL-60 cells and the mouse skin 
tumorigenesis model. Effects of structure-related flavone/isoflavones on hydrogen peroxide 
(H2O2) production by 12-O-tetradecanoylphorbol-13-acetate (TPA)-activated HL-60 cells 
and superoxide anion (O2-) generation by xanthine/xanthine oxidase were compared. Studies 
showed that genistein significantly inhibits TPA-induced proto-oncogene expression (c-fos) 
in mouse skin in a dose-dependent manner. In a two-stage skin carcinogenesis study, low 
levels of genistein (1 and 5μM) significantly prolong tumor latency and decrease tumor 
multiplicity by approximately 50%. Of tested isoflavones, genistein is the most potent 
inhibitor among TPA-induced H2O2 formation by (dimethyl sulfoxide) DMSO-differentiated 
HL-60 cells. In contrast, genistein, apigenin, and prunectin are equally potent in inhibiting 
O2- generation by xanthine/xanthine oxidase, with daidzein showing a moderate inhibitory. 
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Although these results suggested that the antioxidant properties of isoflavones were 
structurally related and the hydroxy group at Position 4' was crucial in both systems and 
dietary administration of 250 ppm genistein for 30 days significantly enhances the activities 
of antioxidant enzymes in the skin and small intestine of mice. It was confirmed that 
genistein's antiproliferative effects and antioxidant properties may be responsible for its 
anticarcinogenic effect. Its high content in soybeans and relatively high bioavailability favor 
genistein as a promising candidate for the prevention of human cancers. In another 
experimental prostate tumor study, Zhou et al. (1999) characterized the ability of dietary 
soybean components to inhibit growth of transplantable prostate adenocarcinomas and tumor 
cell proliferation and angiogenesis of transplantable prostate cancer in immunodeficient 
mice. Soy isoflavones (genistein or daidzein) or soy phytochemical concentrate inhibited the 
growth of prostate cancer cells LNCaP, DU 145 and PC-3 in vitro. G2-M arrest and DNA 
fragmentation consistent with apoptosis of prostate cancer cells were also observed at 
concentrations causing growth inhibition. In contrast, the in vitro proliferation of vascular 
endothelial cells was inhibited by soy phytochemcials at much lower concentrations. Mice 
inoculated subcutaneously with LNCaP cells (2 x 10(6)) were randomly assigned to one of 
the six dietary groups based on the AIN-76A formulation for 3 wk. A 2 x 3 factorial design 
was employed with two protein sources (20%, casein vs. soy protein) and three levels of soy 
phytochemical concentrate (0, 0.2 and 1.0% of the diet). The ability of dietary soy 
phytochemical concentrate and soy protein isolate to inhibit the growth of the LNCaP human 
prostate cancer in severe combined immune-deficient mice was evaluated. Compared with 
casein-fed controls, the tumor volumes after 3 wk were reduced by 28% by soy protein with 
0.2% soy phytochemical concentrate (P < 0.05), 30% by 1.0% soy phytochemical 
concentrate (P < 0.05) and 40% by soy protein with 1.0% soy phytochemical concentrate (P 
< 0.005). Histologic examination of tumor tissue showed that consumption of soy products 
significantly reduced tumor cell proliferation, increased apoptosis and reduced microvessel 
density. These data suggested that dietary soy products may inhibit experimental prostate 
tumor growth through a combination of direct effects on tumor cells and indirect effects on 
tumor neovasculature. 
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         Furthermore, the growth inhibition of cancer cells could be due to the cell-cycle 
arrest, which ultimately results in ceasing cell proliferation. Davis et al. (1998) also showed 
that genistein induced a G2/M cell-cycle arrest in PC3 and LNCaP prostate cancer cells. The 
inhibition of cell proliferation by genistein could also be due to increased apoptosis. Lian et 
al. (1998) & Li et al. (1999) showed that genistein induced apoptosis in MDA-MB-231, 
MDA-MB-435, and MCF-7 breast cancer cells; PC3 and LNCaP prostate cancer cells; H460 
and H322 non-small-cell lung cancer cells; and HN4 head and neck squamous carcinoma 
cells. Onozawa et al. (1999) reported soy isoflavone-supplemented diets prevented the 
development of adenocarcinomas in the prostate and seminal vesicles in a rat carcinogenesis 
model.  
      Akt signaling pathway also plays an important role in cell growth and apoptosis. 
Akt, also referred to as PKB, contains an amino-terminal pleckstrin homology domain that 
binds phosphorylated lipids at the membrane in response to activation of phosphatidylinositol 
3 kinase (PI3 kinase) (Franke et al. 1997). Because genistein is a protein-tyrosine kinase 
inhibitor but not reported to be a serine kinase inhibitor, Li et al. (2002) examined whether 
Akt is phosphorylated and, thereby, activated in PC3 cells under normal growth conditions 
and whether the phosphorylation of Akt is affected in genistein-treated cells. Western blot, 
immunoprecipitation, and kinase assays were conducted. They demonstrated that genistein 
inhibited the activation of Akt kinase activity, which may result in the inhibition of survival 
signals and thereby induce the apoptotic processes.     
      Nuclear factor kappaB (NF-kappaB) signaling pathway is one of cell signaling 
pathways that plays an important role in cell proliferation. The NF-kappaB family, one of the 
transcription factors, is composed of five proteins—RelA (p65), RelB, Rel, NF-kappaB1 
(p50), and NF-kappaB2 (p52)—each of which may form homo- or heterodimers (Verma et 
al. 1995). Chemotherapeutic agents are known to induce NF-kappaB activity in tumor cells, 
resulting in lower cell killing and drug resistance. In contrast, genistein has been shown to 
inhibit the activity of NF-kappaB and the growth of various cancer cells without causing 
systemic toxicity. Li et al. (2005) reported inactivation of nuclear factor-kappaB by soy 
isoflavone genistein contributed to increase apoptosis induced by chemotherapeutic agents in 
human cancer cells. They investigated whether the inactivation of NF-kappaB by genistein 
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before treatment of various cancer cells with chemotherapeutic agents could lead to better 
tumor cell killing as tested by animal studies and by in vitro studies using gene transfections. 
PC-3 (prostate), MDA-MB-231 (breast), H460 (lung), and BxPC-3 (pancreas) cancer cells 
were pretreated with 15 to 30 micromol/L genistein for 24 hours and then exposed to low 
doses of chemotherapeutic agents for an additional 48 to 72 hours. The animal experiments 
of p65 cDNA transfection and p65 small interfering RNA studies clearly showed that a 
specific target (NF-kappaB) was affected in vivo. In in vitro studies, they found that 15 to 30 
micromol/L genistein combined with 100 to 500 nmol/L cisplatin, 0.5 to 2 nmol/L docetaxel, 
or 50ng/mL doxorubicin resulted in significantly greater inhibition of cell growth and 
induction of apoptosis compared with either agent alone. Moreover, the NF-kappaB activity 
was significantly increased within 2 hours of cisplatin and docetaxel treatment and the NF-
kappaB inducing activity of these agents was completely abrogated in cells pretreated with 
genistein were found. Collectively, these results clearly suggested that genistein pretreatment 
inactivates NF-kappaB and may contribute to increased growth inhibition and apoptosis 
induced by cisplatin, docetaxel, and doxorubicin in prostate, breast, lung, and pancreatic 
cancer cells. Theses results warranted carefully designed clinical studies investigating the 
combination of soy isoflavones and commonly used chemotherapeutic agents for the 
treatment of human cancers.     
          The effects of dietary flavonoids on cytochrome P450 (CYP) enzymes related 
to carcinogen metabolism also is relaed to cancer development. The flavonoid effects on 
CYP enzymes involved in the activation of procarcinogens (phase I monooxygenase 
enzymes) and phase II enzymes, largely responsible for the detoxification of carcinogens. A 
number of naturally occurring flavonoids have been shown to modulate the CYP450 system, 
including the induction of specific CYP isozymes, and the activation or inhibition of these 
enzymes (Conney 2003).          
          CYP enzymes (phase I monooxygenase enzymes) are widely known for their 
role in the metabolism of drugs and other foreign compounds. Thus, modulation of this 
enzyme system can influence the metabolism of xenobiotics, producing effects of 
pharmacological and toxicological importance. Many carcinogens are metabolized by CYP 
enzymes to either biologically inactive metabolites or to chemically reactive electrophilic 
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metabolites that covalently bind to DNA producing carcinogenicity. Therefore, induction of 
either phase I or phase II enzymes can result in increased detoxification of carcinogens 
(Conney 2003). CYP19, also known as aromatase (11β-hydroxysteroid dehydrogenase), is 
one member of the cytochrome P450 enzyme superfamily. This enzyme represents a crucial 
enzyme of estrogen biosynthesis. Increased expression of aromatase has been observed in 
breast cancer tissue (Miller et al. 1990 &Zhou et al. 1996). Flavones (chrysin, baicalein, and 
galangin), flavanone (naringenin) and isoflavones (biochanin A) inhibited the activity of 
human aromatase in Chinese hamster ovary (CHO) cells, thus decreasing estrogen 
biosynthesis and circulating estrogen levels (Kao et al. 1998). Isoflavone, equol was potent 
inhibitor of the ovarian aromatase activity in rainbow trout and also showed inhibitory effect 
on human placental aromatase (Pelissero et al. 1996). 
          Kao et al. (1998) investigated flavone and isoflavone phytoestrogens whether 
to act as competitive inhibitors of cytochrome P450 aromatase with respect to the androgen 
substratea in site-directed mutagenesis study. Aromatase is the enzyme that converts 
androgen to estrogen; therefore, these plant chemicals are thought to be capable of modifying 
the estrogen level in women. In this study, the inhibition profiles of four flavones [chrysin (5, 
7-dihydroxyflavone), 7,8-dihydroxyflavone, baicalein (5,6,7-trihydroxyflavone), and 
galangin (3,5,7-trihydroxyflavone)], two isoflavones [genistein (4,5,7-trihydroxyisoflavone) 
and biochanin A (5,7-dihydroxy-4-methoxyisoflavone)], one flavanone [naringenin (4, 5,7-
trihydroxyflavanone)], and one naphthoflavone (alpha-naphthoflavone) on the wild-type and 
six human aromatase mutants (I133Y, P308F, D309A, T310S, I395F, and I474Y) were 
determined. In combination with computer modeling, the binding characteristics and the 
structure requirement for flavone and isoflavone phytoestrogens to inhibit human aromatase 
were obtained. These compounds were found to bind to the active site of aromatase in an 
orientation in which rings A and C mimic rings D and C of the androgen substrate, 
respectively. 
                  Activation of phase II detoxifying enzymes, such as UDP-glucuronyl transferase 
(UGT), glutathione S-transferase (GST), and NAD(P)H, quinone oxidoreductase (QR) by 
flavonoids results in the detoxification of carcinogens and represents one mechanism of their 
anticarcinogenic effects (Chen at al. 2004). A significant negative correlation was 
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demonstrated between GST enzyme activity and tumor incidence in the mucosa along the 
human gastrointestinal tract, suggesting the importance of GSTs in cancer prevention (Peters 
et al. 1993). GSTs have a considerably important role in the detoxification of carcinogens 
(Hayes et al. 1995). Genistein and daidzein were found to increase QR activities in 
Hepa1c1c7 cells (Yannai et al. 1998).    
    
F. Bioavailability of isoflavones          
 
   Bioavailability is defined as the proportion of a compound that appears in plasma 
over time and the proportion excreted in the urine and feces compared to the amount 
ingested, when the compound is administered orally. From a toxicological perspective then, 
bioavailability is a measure of the potential for entry of a chemical into sites of action and 
implies movement of a chemical into the systemic circulation because this is a good 
indication of the biologically effective dose. Casarett and Doull (2001) define bioavailability 
as the fraction of the oral dose that is absorbed. That means that bioavailability equals to 
mass of chemical absorbed compared with mass of chemical administered.    Food matrices 
in which isoflavones are found and chemical differences that separate daidzein, genistein and 
glycitein have also been studied with respect to possible variations in isoflavone. Mostly, 
bioavailability of isoflavones focuses on plasma and urinary kinetics as well as microbial 
metabolism (Birt et al. 2001; Xu et al 2002).  
The area of isoflavone bioavailability is complex and wide range of variability in 
response to dietary isoflavones. Many human studies and animal models have been 
established to study bioavailability of isoflavones. Some focused on understanding how 
isoflavones are metabolized in the body including plasma kinetics as well as urinary and 
fecal excretion. Hendrich and co-workers indicated that a variety of factors affected 
bioavailability of soybean isoflavones.  
Xu et al. (1994) showed that daidzein is a more bioavailable soymilk isoflavone than 
genistein in adult women while glycitein was not measured. Xu et al. (1994) fed 12 women 3 
doses of isoflavones (2.5, 4.8 and 7.4 µmol/kg BW from soymilk powder; 44% genistein and 
56% daidzein). Plasma levels of daidzein and genistein were similar to each other at time 6.5 
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and 24h following ingestion at all 3 doses. Urinary recovery of daidzein and genistein were 
21% and 9% of the ingested dose, respectively and fecal excretion was 1-2% ingested dose. 
The amounts of isoflavone recovered in the urine were proportional to the ingested dose 
(dose-response between amounts fed and those recovered in the urine). Total isoflavone 
excreted in the urine was significantly higher in 0-12 h compared to 12-24 h following 
ingestion by a factor of 2 to 3, meaning that isoflavone absorption and metabolism is a fast 
process, occurring mostly in the first 12 h after ingestion and disappearing almost completely 
after 24 h. Based on urinary excretion, Xu et al. (1994) concluded that daidzein was more 
bioavailable than genistein. Soybean milk isoflavones seem to be 85% degraded in the 
intestine, daidzein may be sufficient to exert some health-protective effects. 
      Xu et al. (1995) found that the efficiency of absorption of soymilk isoflavones 
varied from 13 to 35%, depending on individual gut microflora. Xu et al. (1995) performed a 
similar study to that of Xu et al. (1994) with three doses of isoflavones fed (3.4, 6.9 and 10.3 
µmol isoflavones/kg body weight; n=7 women), but looked at the individual results and 
found that 2 subjects had significantly higher fecal excretion of isoflavones compare to the 5 
others (about 6% vs. 0.6% of the ingested dose, respectively and regardless of the dose fed). 
48 h urinary recovery was 16±4% and 10±4% of the ingested dose for daidzein and genistein, 
respectively in the 5 subjects with low fecal excretion. The two subjects with high fecal 
excretion had 32±5% and 37±6% urinary recovery expressed as a % ingested dose. As for 
plasma, subjects with high fecal and urinary excretion had plasma isoflavone level 2.5-fold 
higher compare to subjects who were low isoflavone excreters. This study established the 
principles of phenotypes of isoflavone bioavailability, in which people can be grouped as 
high apparent absorbers (high urinary, plasma and fecal isoflavone contents) or low apparent 
absorbers. Moreover, high apparent absorbers do not seem to have as much gut microbial 
activity degrading isoflavones, because they are excreted intact and in greater level in the 
feces those subjects. The role of the gut microflora in determining the extent of isoflavone 
bioavailability became then a factor that could not be overlooked. These two studies 
performed by Xu et al. (1994 & 1995) did not consider bioavailability of glycitein, a minor, 
but still important soy isoflavones.            
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    Zhang et al. (1999; erratum, 2001) indicated urinary daidzein excretion was the 
greatest among that of three isoflavones in moderate fecal degraders and glycitein 
bioavailability was similar to daidzein in humans. On the other hand, comparing with this 
present study with two other studies in our laboratory, glycitein bioavailability was greater 
than daidzein and genistein excretion in hamsters.  
     Hendrich et al. (2001) found that plasma daidzein and genistein concentration was 
negatively correlated with in vitro fecal daidzein and genistein disappearance rate constant (r 
= -0.74, P = 0.04; r = -0.88, P = 0.01, respectively), supporting an important role for gut 
microbial activity in isoflavone bioavailability. Recently Zheng et al. (2003) demonstrated a 
relationship between isoflavone disappearance phenotypes and GTT and suggested that gut 
microorganisms may affect GTT. Among 35 Chinese vs. 33 Caucasian women, Chinese 
subjects who were low degraders of genistein had threefold greater bioavailability of 
genistein than Chinese high degraders. The Chinese who were low isoflavone degraders had 
the average GTT of 40 h vs. 65 h for Chinese high degraders. Caucasian subjects, regardless 
of isoflavone degradation phenotypes, had GTT > 80 h, and less apparent isoflavone 
absorption than did the Chinese subjects who were low degraders of isoflavones. GTT may 
be a crucial determinant of human differences in isoflavone bioavailability. 
       In an animal study, King (1998) compared the bioavailability of daidzein and 
genistein in male Wistar rats fed a soy extract providing 74 µmol genistein and 77 µmol 
daidzein/kg body weight. 48h urinary excretion of daidzein and genistein were 17.4±1.2% 
and 11.9±1.1% of the ingested dose, respectively, while fecal excretion was 2.3±0.5% and 
3.4±0.4%, respectively. As observed in humans (Xu et al. 1994 & 1995; Setchell et al. 2003), 
daidzein was more bioavailable than genistein and the range of urinary excretion is 
comparable to human data. Therefore, not only are rats an interesting model to study 
bioavailability, but also the gut microbial metabolism of humans and rats may share some 
similarities in degrading or metabolizing isoflavones. 
       Using isolated rat small intestine as an ex-vivo animal model, Andlauer et al. 
(2000b), studied the absorption rate and biotransformation of isoflavones daidzin and 
genistin derived from pre-digested tofu (1184 nmol genistein expressed as aglycone/g tofu 
and 572 nmol daidzein expressed as aglycone/g tofu). Tofu also contained small amounts of 
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malonyl-isoflavone and isoflavone aglycone. Of these compounds, 8% genistein and 8.9% 
daidzein appeared at the vascular side, either as aglycone, glucuronide and glucoside. A 3 
and 2-fold increase in the aglycone genistein and daidzein, respectively was found in the 
luminal side. However, no sulfate conjugate were found in this experiment. In another 
experiment with only genistin applied in an isolated rat small intestine, Andlauer et al. 
(2000b) found an absorption rate of about 15%, with glucuronides>aglycones>glucosides 
found on the vascular side. These two studies showed that daidzein and genistein absorption 
rate are similar and that biotransformation occur during the absorption process. However, the 
absence of sulfate conjugate indicated that rat may not be able to produce this conjugate, or 
this process is restricted exclusively to the liver. The presence of isoflavone glucoside on the 
vascular side was surprising and lead to the conclusion that rat may be capable of absorbing 
isoflavone glucoside without cleavage. On the other hand, the very small proportion of 
isoflavone glucosides found may have been related to a leakage in this ex-vivo system. 
    Lee et al. (2005) fed pure synthetic daidzein, genistein, or glycitein to female 
Golden Syrian hamsters (11-12 weeks of age, 10 hamsters/treatment) for 4 weeks and 
reported the urinary isoflavone excretion was glycitein> daidzein>genistein 
(32.2%>4.6%>2.2%). Meanwhile, Renouf et al. (2006) showed similar data in feeding either 
1.18 or 1.77 mmol total isoflavones/kg diet to 19 one-year old hamsters for 10 d in both 
males and females. These results indicated that the microbes in hamsters seem to differ from 
those in humans. They reported similar isoflavone urinary excretion and gut microbial 
degradation patterns compare to humans in Golden Syrian hamster fecal and cecal microbial 
degradation of isoflavones. Daidzein excretion was significantly greater than glycitein and 
genistein excretion in urine and female urinary excretion was significantly greater than male. 
Therefore, this study established Golden Syrian hamsters as a potential animal model to be 
used instead of humans to study some chronic diseases which could not be induced in 
humans, such as cancer.  
Renouf et al. (2005) conducted two separate studies, one focusing on fecal (study #1, 
n=20/sex) and the other on cecal (study #2, n=10/sex) microbial degradation of isoflavones 
in Golden Syrian hamsters. They reported that urinary excretion was significantly lower by 
2-4 fold in males compared to females in both studies. In addition, females from study #1 had 
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significantly greater urinary excretion levels of daidzein (44.2 ± 13.7% vs. 29.6 ± 13.4%), 
glycitein (31.4 ± 11.2% vs. 18.2 ± 8.0%) and genistein (26.7 ± 11.5% vs. 15.8 ± 9.4% 
ingested dose) compared to cecal study #2, respectively. Fecal isoflavone excretion was not 
significantly different between sexes or isoflavones (study #1) and showed extremely low 
levels of excretion (<0.5% ingested dose). In vitro fecal degradation rates from study #1 
showed low degradation levels and no significant correlation between urinary and fecal 
isoflavone excretion. The most importance finding was that cecal isoflavone degradation 
rates (study #2) were much higher than fecal isoflavone degradation rates (study #1) and 
were statistical correlated with urinary excretion of daidzein (R=0.90; p=0.01) and genistein 
(R=0.93; p=0.004). They concluded that Golden Syrian hamsters displayed similar patterns 
of bioavailability of isoflavones compared to humans in terms of apparent absorption, urinary 
excretion and gut microbial degradation.    
Recently, Renouf et al. (2005) showed Bacteroides ovatus, Bacteroides acidifaciens, 
Eubacterium ramulus, Clostridium orbiscindens and Tannerella forsythensis were the major 
human gut microbial species that degraded isoflavones and established that Golden Syrian 
hamsters may be good models to study bioavailability of isoflavones and their possible health 
promoting effects. Renouf et al. (2005) identified high fecal isoflavone degradation rate to 
coincide with distinct fecal bacterial species. Fresh feces from 33 healthy adult subjects (20 
men, 13 women) were incubated anaerobically with isoflavones to assess degradation rates 
using HPLC. Fecal DNA was extracted, bacterial 16S rDNA sequences amplified by 
polymerase chain reaction (PCR) and separated by denaturing gradient gel electrophoresis 
(DGGE). Cluster analysis identified high and low degraders of daidzein, genistein and 
glycitein. DGGE analysis showed that high genistein degraders (n=4; fecal degradation rate 
1.47 ± 0.14h-1) shared 5 bands of greater intensity than found in feces of low genistein 
degraders (n=4; fecal degradation rate 0.146 ± 0.034 h-1) high glycitein degraders (n=4; 0.574 
± 0.299h-1) also shared 5 bands of greater intensity than found in feces of low glycitein 
degraders (n=4; 0.146 ± 0.034 h-1). They also showed concordance with known species from 
the Bacteroides and Prevotella genus as well as the Clostridiales order using sequencing of 
16S rDNA from the bands of interest. After developing two in vitro systems, one rich (rumen 
fluid based brain heart infusion media) and one poor in nutrients (feces incubated overnight 
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in brain heart infusion media), they identified Bacteroides ovatus, Bacteroides acidifaciens, 
Eubacterium ramulus, Clostridium orbiscindens and Tannerella forsythensis as the major 
human gut microbial species that degraded isoflavones under both nutrient rich and poor 
conditions, thus these species may be the most significant ones in degrading isoflavone in the 
human gut. They also concluded that bacterial species shared by both high and low degraders 
with greater amounts in high degraders may be predictors of gut microbial degradation and 
overall bioavailability of isoflavones. Secondary species that may be specific to each 
individual fecal isoflavone degradation rate may be of importance for assessing microbial 
activity and will deserve further attention.    
In summary, bioavailability of isoflavones on plasma kinetics, urinary and fecal 
excretion is now well understood. Isoflavone absorption is a fast process with a maximum 
plasma peak occurring within 12 h after ingestion. Only traces of isoflavone are excreted in 
the urine after 48 h; most of the isoflavones ingested are being excreted within 24-48h. From 
animal and human studies obtained until now, we believed that potential animal models 
could be used to study isoflavone bioavailability. At meantime, in both humans and animals, 
urinary together with fecal excretions are less to 100% of the ingested dose and most of the 
studies have found a cumulative urinary and fecal excretion less 60%, suggesting that a great 
amount of isoflavones disappear in metabolism. There is now good evidence that gut 
microorganisms play an important role in the process of bioavailability. We now know that 
isoflavone bioavailability varies greatly among individuals in terms of the amount of 
isoflavone degradation microbial species which are relatively stable within an individual. 
Interindividual variability in isoflavone bioavailability needs more investigation.         
 
G. Isoflavone toxicity     
 
  Together with the safety of soy isoflavone products use, the toxicity of isoflavone is 
also considered. Some toxicological findings in relation to endocrine disrupters including 
reproductive effects, infertility and thyroid disease due to dietary intake of isoflavones had 
been observed in animals. Hughes et al. (1991a&b) indicated that acute and subacute 
administration of the phytoestrogen genistein blocked the gonadotropin-releasing hormone-
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induced rise of luteinizing hormone in rats. The prenatal exposure to genistein in the 
environment could influence sexual differentiation in pregnant rats (Levy et al. 1995).       
Yellayi et al. (2002) conducted an ovariectomized C57BL/6 mouse experiment with 
subcutaneous injection of genistein (2, 8, 20, 80, 200mg/kg body weight) and indicated that 
isoflavones may have a negative impact on thymus. They found that thymus weight was 
decreased compared to control in a dose response manner with the 4 highest doses in the 8, 
20, 80 and 200 mg/kg per day genistein groups being significantly different from the control 
(17 to 78%) which had a subsequent negative effect on immune function, including keyhole 
limpet haemocyanin (KLH)-specific antibody titers, CD4+CD8− T cells as a percentage of 
splenic lymphocytes and relative percentages of lymphocytes. To compare serum genistein 
levels in this injected mice with those reported for soy-fed human infants which plasma 
isoflavone levels of 2.0–6.6 μmol/liter and genistein levels of 1.5–4.4 μmol/liter have been 
reported in 4-month-old human infants (Setchell et al. 1997), serum genistein in mice dosed 
with 8 mg/kg were comparable to those in soy-fed infants at 0.5, 1, and 2 h; and the 20 mg/kg 
dose produced serum genistein levels 2- to 3-fold greater than maximal levels reported in 
soy-fed infants. Because the peak levels of maximal serum genistein in soy-fed infants were 
similar to that in mice after 8 mg/kg genistein injection, the possibility that serum genistein 
concentrations found in soy-fed infants may be capable of producing thymic and immune 
abnormalities. However, it is still problematic to compare effects of specific doses of 
genistein on mice and humans because ingestion of a compound normally tends to lower 
blood levels than injection and mice may be different with humans in genistein metabolism.   
               Hughes et al. (1991a) compared tonic luteinizing hormone (LH) secretion and 
gonadotropin releasing hormone-induced LH responses following high intravenous (iv) dose 
pretreatments with genistein or estradiol and determined effects of genistein or estradiol 
pretreatments on progesterone (P)-induced secretion of LH. Mature Charles River CD rats 
were ovariectomized and intraatrial cannulae were placed after 2 to 5 weeks later. Serial 
blood samples were drawn and LH was   measured. In three experiments, genistein or 
estradiol was administered acutely by gavage or iv, and subcutaneously (sc) oil 3 days prior 
to cannulation and sampling. Acute po administration of vehicle or genistein (0.1, 1.0, and 10 
mg/kg BW) had no effect on tonic LH while estradiol suppressed LH at all doses (0.1, 1.0, 
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and 10 mg/kg BW). Acute iv administration of vehicle and higher doses of genistein (1 and 
10 mg/kg BW) had no effect on tonic LH, while the lowest dose genistein (0.1 mg/kg BW) 
and all doses of estradiol (0.1, 1, and 10 mg/kg BW) suppressed tonic LH. They concluded 
that acute intravenous administration of the phytoestrogen genistein blocked the 
gonadotropin-releasing hormone-induced rise of luteinizing hormone in ovariectomized rats. 
             In the second study, Hughes et al. (1991b) determined whether subacute 
administration of genistein or the mycoestrogens zearalenone and zearalenol would affect 
GnRH-induced or progesterone-induced LH secretion in ovariectomized rats. The same 
animal species and similar feeding doses were used in this study. They found that subacute 
administration of genistein, zearalenone, or zearalenol did not inhibit tonic LH secretion in 
the ovariectomized rat and confirmed genistein and zearalenol did block GnRH-induced LH 
secretion. In Hughes et al. studies, because they did not measure the serum genistein 
concentrations, we can not compare with humans, at least soy-fed human infants as 
mentioned above.     
              Furthermore, Levy et al. (1995) determined whether exposure to genistein during 
critical periods of development could alter morphologic and physiologic markers of sexual 
differentiation. They characterized the effects of in utero treatment with genistein on birth 
weight and anogenital distance (AGD) at birth, gonadotropin releasing hormone (GnRH) 
stimulated luteinizing hormone (LH) secretion, volume of the sexually dimorphic nucleus in 
the preoptic area of the hypothalamus (SDN-POA), puberty onset, and vaginal cyclicity in 
pregnant Charles River CD rats. The rats were injected subcutaneously (sc) daily on gestation 
day 16-20 with either 25mg genistein (G25), 5mg genistein (G5), 5μg diethylstillbestrol 
(DES), 50μg estradiol benzoate (E), or corn oil alone for controls. Birth weights and 
anogenital distance were taken and exposed progeny were subsequently used in two 
experiments. In Experiment 1 intra-atrial catheters were placed in adult castrated rats, GnRH 
was given iv, serial blood samples were drawn and sera were assayed for LH by 
radioimmunoassay (RIA). Brains obtained by subsequent decapitation were saved for 
histology. In Experiment 2, females were monitored for timing of vaginal opening as a 
marker of puberty onset, and vaginal smears were taken to monitor cyclicity. G25-treated 
females and DES-and E-treated animals of both sexes had decreased weights at birth 
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compared with controls. G5- and E-treated animals of both sexes and DES males had smaller 
AGD than controls. They found no significant differences in pituitary responsiveness to 
GnRH among treatment groups. G5-treated females had delayed puberty onset, and DES-
treated females had atypical vaginal cycles in comparison with controls. The results 
concluded that prenatal exposure to genistein in the environment could influence sexual 
differentiation. Genistein did mimic other estrogens' effects on AGD and birth weight and 
had a unique influence on puberty onset. However, they also can not determine the relevance 
to humans because genistein injection is different with human ingestion of this compound.  
            Gametogenesis and reproductive efficiency of trout were decreased in feeding 
genistein-containing diets to rainbow trout (Oncorhynchus mykiss) for one year (Bennetau-
Pelissero et al. 2001). In this study, they fed diets including 0, 500, or 1000 ppm genistein to 
groups of rainbow trout undergoing their first gametogenesis and until spawning. They found 
that growth performance of rainbow trout was not affected by dietary treatments. Plasma 
cholesterol levels were equivalent between groups. In males, a decrease in testosterone levels 
was observed. There was a significantly reduced 17alpha, 20beta-(OH)(2)-progesterone. 
Testicular development was accelerated in genistein-fed fish, and sperm motility and 
concentration were decreased in a dose-dependent manner at spawning. In females, a 
significant increase in plasma of vitellogenin (VTG) occurred only at the beginning and at 
the end of oogenesis. Testosterone levels were decreased at the beginning of oogenesis. Both 
betaFSH and betaLH were decreased by genistein, whereas spawning was delayed only in 
females fed the diet with 500 ppm of genistein. Gamete quality was impaired only in this 
group, as underlined by a lower percentage of ovulating females, a lower fertilization rate, 
and a lower viability of fry. These results may be explained by the agonistic/antagonistic 
effect of genistein on estrogen functions.  
                In human studies, there are very limited data on sexual and reproductive 
development or fertility related to isoflavone toxicity. Strom et al. (2001) investigated the 
association between infant exposure to soy formula and health in young adulthood, with an 
emphasis on reproductive health. The retrospective cohort study conducted from 248 adults 
aged 20 to 34 years were fed soy formula and 563 were fed cow milk formula during infancy. 
Self-reported pubertal maturation, menstrual and reproductive history, height and usual 
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weight, and current health, compared based on type of formula exposure during infancy. 
They did not find statistically significant differences between groups in either women or men 
for more than 30 outcomes except slightly longer duration of menstrual bleeding and 
discomfort with menstruation in women who had been fed soy formula. They concluded that 
exposure to soy formula did not appear to lead to different general health or reproductive 
outcomes than exposure to cow milk formula. 
                In a subsequent review, Mendez et al. (2002) conducted to evaluate various 
measures of infant health and development in clinical studies comparing modern soy-based 
formulae with other diets. They concluded that modern soy-based formulae supported normal 
growth and nutritional status in healthy term infants and did not provide evidence of 
meaningful differences in timing of maturation, sexual development or fertility in adolescents 
or adults. In another study, Takimoto et al. (2003) evaluated toxicity from pilot data on in 
vivo effects on protein-tyrosine phosphorylation. They conducted the pharmacokinetic 
parameters of two different preparations of unconjugated soy isoflavones, PTI G-2535 and 
PTI G-4660 (which contain 43% and 90% genistein, respectively) in human subjects with 
cancer. Four group patients were given single doses of each preparation. They received oral 
genistein at 2, 4, or 8 mg/kg sequentially. Pharmacokinetic sampling was performed after 
each dose, and tyrosine phosphorylation was measured in proteins extracted from peripheral 
blood mononuclear cells. Only one of 13 patients treated developed a treatment-related rash. 
No other toxicities were observed.  
               However, Bloedon et al. (2002) found a few symptom of nausea, pedal edema, and 
breast tenderness related to isoflavone toxicity in excessive intakes. They performed safety 
and pharmacokinetic studies of purified unconjugated isoflavone preparations containing 
genistein, daidzein, and glycitein in postmenopausal women. Twenty-four healthy 
postmenopausal women ingested a single dose of 1 of 2 purified isoflavone preparations. 
Toxicity studies were performed 24 h and 3, 6, 14, and 30 d after isoflavone administration. 
They observed a 7% decrease in systolic and diastolic blood pressure and a 32% decrease in 
the neutrophil count 24 h after treatment with formulation. No other toxicities were found 
from measurements of clinical signs. The terminal plasma half-lives for free genistein, 
daidzein, and glycitein averaged 3.8, 7.7, and 3.4 h, respectively. The terminal pseudo half-
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lives for total genistein and total daidzein in plasma averaged 10.1 and 10.8 h, respectively. 
The estimated bioavailabilities of both total genistein and total daidzein from each of the 2 
formulations were not significantly different. They indicated the pharmacokinetic data 
suggested that chronic dosing at 12–24-h intervals would not lead to progressive 
accumulation of these isoflavones. 
            In conclusion, with regard to isoflavone toxicity, although the studies described above 
demonstrated that isoflavone interfered with endocrine and reproductive processes in 
animals, very few toxicities have been found in human. There is no doubt that the dosage, 
route and timing of exposure during toxicological studies are very important factors in 
modifying end points associated with hormone disruption. However, most of the 
toxicological studies done were using injections not oral exposures; it is difficult to 
extrapolate those toxic doses to humans based on injection doses, thus more oral dose 
response of specific toxic doses for isoflavone in animal models are needed.   
 
H. References 
 
Adams MR, Golden DL, Anthony MS, Register TC, Williams JK. 2002 The inhibitory effect 
of soy protein isolate on atherosclerosis in mice does not require the presence of LDL 
receptors or effects on plasma lipoproteins. J. Nutr. 132:43–49. 
 
Adams MR, Golden DL, Williams JK, Franke AA, Register TC & Kaplan JR. 2005 Soy 
protein containing isoflavones reduces the size of atherosclerotic plaques without affecting 
coronary artery reactivity in adult male monkeys. J. Nutr. 135, 2852–2856. 
 
Adlercreutz CH, Goldin BR, Gorbach S.L, Hockerstedt KA, Watanabe S, Hamalainen EK, 
Markkanen MH, Makela TH, Wahala KT, Adlercreutz T. 1995 Soybean phytoestrogen 
intake and cancer risk. J. Nutr. 125(3 Suppl.): 757S–770S. 
 
Adlercreutz CHT, Goldin BR, Gorbach SL, Höckerstedt KAV, Watanabe S, Hämäläinen EK. 
1995 Soybean phytoestrogen intake and cancer risk. J. Nutr. 757–770.  
 
 
 
53
 
Anderson JW, Johnstone BM, Cook-Newell ME. 1995 Meta-analysis of effects of soy 
protein intake on serum lipids in humans. N. Engl. J. Med. 333:276-282. 
 
Anderson RL, Wolf WJ. 1995 Compositional changes in trypsin inhibitors, phytic acid, 
saponins and isoflavones related to soybean processing. J. Nutr. 125:581S-588S 
 
Andlauer W, Kolb J and Furst P. 2000b Isoflavones from tofu are absorbed and metabolized 
in the isolated rat small intestine. J. Nutr. 130: 3021-3027. 
 
Anthony MS, Clarkson TB, Bullock BC, Wagner JD. 1997 Soy protein versus soy 
phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male 
cynomolgus monkeys. Arterioscler Thromb. Vasc. Biol. 17:2524-2531.  
 
Anthony MS, Clarkson TB, Williams JK. 1998 Effects of soy isoflavones on atherosclerosis: 
potential mechanisms. Am. J. Clin. Nutr. 68: 1390S–1393S. 
 
Arjmandi BH, Birnbaum R, Goyal NV, Getlinger MJ, Juma S, Alekel L, Hasler CM, Drum 
ML, Hollis BW, Kubreja SC. 1998 Bone-sparing effect of soy protein in ovarian hormone-
deficient rats is related to its isoflavone content. Am. J. Clin. Nutr. 68 (suppl.): 1364S-1368S. 
 
Baum JA, Teng H, Erdman JW Jr, Weigel RM, Klein BP, Persky VW, Freels S, Surya P, 
Bakhit RM, Ramos E, Shay NF, Potter SM. 1998 Long-term intake of soy protein improves 
blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor 
messenger RNA in hypercholesterolemic, postmenopausal women. Am. J. Clin. Nutr. 68: 
545–551.  
 
Bennetau-Pelissero C, Breton B, Bennetau B, Corraze G, Le Menn F, Davail-Cuisset B, 
Helou C and Kaushik SJ. 2001 Effect of genistein-enriched diets on the endocrine process of 
 
 
 
54
gametogenesis and on reproduction efficiency of the rainbow trout Oncorhynchus mykiss. 
Gen. Comp. Endocrinol. 121, pp. 173–187.          
 
Birt DF, Hendrich S, Alekel DL, Anthony M. 2004 Soybean and the prevention of chronic 
human disease. In Soybeans: improvement, production and uses, 3rd ed. pp 1047-1117. 
American society of Agronomy. Crop Science Society of America, Soil Science Society of 
America, Madison, WI. 
 
Birt DF, Hendrich S, Wang W. 2001 Dietary agents in cancer prevention: flavonoids and 
isoflavonoids. Pharmac. & Therap. 90: 157-177. 
 
Birt DF, Hendrich S, Wang W. 2001 Dietary agents in cancer prevention: flavonoids and 
isoflavonoid. Pharmac& Therap. 90: 157-177.       
 
Blair RM, Appt SE, Bennetau-Pelissero C, Clarkson TB, Anthony MS, Lamothe V, Potter 
SM. 2002 Dietary soy and soy isoflavones have gender-specific effects on plasma lipids and 
isoflavones in golden Syrian f(1)b hybrid hamsters. J. Nutr. 132:3585–3591. 
 
Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, Thomas BF, 
Albright C, Busby MG, Crowell JA, Zeisel SH. 2002 Safety and pharmacokinetics of 
purified soy isoflavones: single-dose administration to postmenopausal women. 
Am. J. Clin. Nutr. 76(5):1126-37.   
 
Boker LK, Van de Schouw YT, De Kleijin MJJ, Jacques PF, Grobbee DE and Peeters PHM. 
2002 Intake of dietary phytooestrogens by Dutch women. J. Nutr. 132: 1319-1328. 
 
Bord S, Horner A, Beavan S, Compston J. 2001 Estrogen receptors alpha and beta are 
differentially expressed in developing human bone. J. Clin. Endocrino.l Metab. 86, pp. 2309–
2314. Chemical Toxicology 42, 1497– 1503. 
 
 
 
 
55
Casarett and Doull's Toxicology: The Basic Science of Poisons, 6th Ed. C.D. Klaassen. 
McGraw-Hill: New York, NY. 2001. 1236 pp. ISBN 0-07-134721-6. 
 
Chen C, Kong AN. 2004 Dietary chemopreventive compounds and ARE/EpRE signaling, 
Free Radic. Biol. Med. 36, pp. 1505–1516.       
 
Chen X, Garner SC, Quarles LD, Anderson JJB. 2003 Effects of genistein on expression of 
bone markers during MC3T3-E1 osteoblastic cell differentiation. J. Nutr. Biochem. 14, pp. 
342–349. 
 
Colacurci N, Chiantera A, Fornaro F, de Novellis V, Manzella D, Arciello A, Chiantera V, 
Improta L, Paolisso G. 2005 Effects of soy isoflavones on endothelial function in healthy 
postmenopausal women. Menopause. 12(3):299-307.  
 
Conney AH. 2003 Enzyme induction and dietary chemicals as approaches to cancer 
chemoprevention: the Seventh DeWitt S, Goodman Lecture. Cancer Res. 63, pp. 7005–7031.  
 
Croft KD. 1998 The chemistry and biological effects of flavonoids and phenolic acids. Ann. 
N Y Acad. Sci. 854, 435–442.    
 
Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. 1999 A randomized trial 
comparing the effect of casein with that of soy protein containing varying amounts of 
isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med. 159:2070–
2076. 
 
Dang ZC, Audinot V, Papapoulos SE, Boutin JA,  Lowik CW. 2003 PPARg as a molecular 
target for the soy phytoestrogen genistein. J. Biol. Chem. 278: 962–967.  
 
 
 
 
56
Davis J, Steinle J, Higginbotham DA, Oitker J, Peterson RG, Banz WJ. 2005 Soy protein 
influences insulin sensitivity and cardiovascular risk in male lean SHHF rats. Horm. Metab. 
Res. 37(5):309-15. 
 
Davis JN, Singh B, Bhuiyan M, Sarkar FH. 1998 Genistein-induced upregulation of 
p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. 
Nutr. Cancer 32(3): 123–131.   
 
Day AJ, Canada FJ, Diaz JC, Kroon PA, Mclauchlan R, Faulds CB, Plumb GW, Morgan 
MRA, Williamson G. 2000 Dietary flavonoid and isoflavone glycosides are hydrolyzed by 
the lactase site of lactase phlorizin hydrolase. FEBS Letters: 468: 166-170. 
 
Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ and Morgan MR. 1998 
Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver 
beta-glucosidase activity. FEBS Letters: 436: 71–75.  
 
De Kleijn MJJ, Van der Schouw YT, Wilson PWF, Adlercreutz H, Mazur W, Grobbee DE, 
Jacques PF. 2001 Intake of dietary phytooestrogens is low in postmenopausal women in the 
United States: the Framingham study. J. Nutr. 131: 1826-1832. 
 
Dent SB, Peterson CT, Brace LD, et al. 2001 Soy protein intake by perimenopausal women 
does not affect circulation lipids and lipoproteins or coagulation and fibrinolytic factors. J 
Nutr 131:2280–7. 
 
Diaz MN, Frei B, Vita JA, Keaney JF Jr. 1997 Antioxidants and atherosclerotic heart disease. 
N. Engl. J. Med. 337:408-16. 
 
Dooley KA, Bennett MK & Osborne TF. 1999 A critical role of cAMP response element-
binding protein (CREB) as a co-activator in sterol-regulated transcription of 3-hydroxy-3-
methylglutaryl coenzyme A synthase promoter.  J. Biol. Chem.  274:5285-5291. 
 
 
 
57
    
Duncan AM, Phipps WR, Kurzer MS. 2003 Phyto-oestrogens. Best Pract Res Clin 
Endocrinol Metab 17:253–271. 
 
Erdman JW Jr, Badger TM, Lampe JW, Setchell KD, and Messina M. 2004 Not all soy 
products are created equal: caution needed in interpretation of research results. J Nutr 134: 
1229S–1233S. 
 
Franke TF, Kaplan DR, Cantley LC. 1997 PI3K: downstream AKTion blocks apoptosis. 
Cell. 88(4): 435–437. 
 
Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodger GM. 1997 Homocysteine, a risk 
factor for premature vascular disease and thrombosis, induces tissue factor activity in 
endothelial cells. Arterioscler Thromb. 13:1327-1333. 
 
Gardner CD, Newell KA, Cherin R, Haskell WL. 2001 The effect of soy protein with or 
without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic 
postmenopausal women. Am. J. Clin. Nutr. 73: 728–735. 
 
Greaves KA, Wilson M D, Rudel LL, Williams JK & Wagner JD. 2002 Consumption of soy 
protein reduces cholesterol absorption compared to casein protein alone or supplemented 
with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgous 
monkeys. J. Nutr. 130:820-826. 
 
Gutteridge JM, Swain J. 1993 Lipoprotein oxidation: the ‘fruit and vegetable gradient’ and 
heart disease. Br J Biomed Sci. 50:284-8. 
 
Hawksworth G, Drasar BS, Hill M. 1971 Intestinal bacteria and the hydrolysis of glycosidic 
bonds. J. Med. Microbiol. 4: 451-459. 
 
 
 
 
58
Hayes JD and Pulford DJ. 1995 The glutathione S-transferase supergene family: regulation of 
GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. 
Crit. Rev. Biochem. Mol. Biol. 30, pp. 445–600.  
 
Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. 1998 Nutritional and 
socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. 
Cancer Inst.  90(21): 1637–1647. 
 
Hendrich S, Murphy PA. 2001 Isoflavones: source and metabolism. Wildman, R.E.C. eds. 
Handbook of Nutraceuticals and Functional Foods. 2001 CRC Press LLC Boca Raton, FL.. 
 
Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. 2001 Beneficial effects of a 
soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 
diabetic subjects. Diabetes Care 24:228–33. 
 
Hirvonen MR, Brune B, Lapetina EG. 1996 Heat shock proteins and macrophage resistance 
to the toxic effects of nitric oxide. Biochem. J. 315(Pt 3):845–849.  
 
Hodgson JM, Puddey IB, Beilin LJ, Mori TA, Burke V, Croft KD & Rogers PB. 1999 
Effects of isoflavonoids on blood pressure in subjects with high-normal ambulatory blood 
pressure levels: a randomized controlled trial. Am. J. Hypertens. 12:47-53.  
 
Honoré EK, Williams JK, Anthony MS, Clarkson TB. 1997 Soy isoflavones enhance 
coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril. 67:148-154.  
 
Honoré EK, Williams JK, Anthony MS. 1995 Enhancement of coronary vasodilation by soy 
phytoestrogens and genistein. Circulation. 92:1:349. 
 
 
 
 
59
Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL & Wang X. 1993 SREBP-
2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by 
binding to a sterol regulatory element. Proc. Natl. Acad. Sci U.S.A. 90:11603-11607.  
 
Hughes CL Jr, Kaldas RS, Weisinger AS, et al. 1991a Acute and subacute effects of naturally 
occurring estrogens on luteinizing hormone secretion in the ovariectomised rat: part 1. 
Reprod. Toxicol. 5:127–32.  
 
Hughes CL Jr, Chakinala MM, Reece SG, Miller RN, Schomberg DW Jr, Basham KB. 
1991b Acute and subacute effects of naturally occurring estrogens on luteinizing hormone 
secretion in the ovariectomized rat: Part 2. Reprod. Toxicol. 5(2):133-7.  
 
 
 
Hur HG, Beger RD, Heinze TM, Lay JO Jr, Freeman JP, Dore J, Rafii F. 2002 Isolation of an 
anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. 
Arch Microbiol 178:8–12. 
 
Hur HG, Lay JO, Beger RD Jr., Freeman JP and Rafii F. 2000 Isolation of human intestinal 
bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. Arch. 
Microbiol. 174: 422–428.  
 
Hwang J, Wang J, Morazzoni P, Hodis HN, Sevanian A. 2003 The phytoestrogen equol 
increases nitric oxide availability by inhibiting superoxide production: an antioxidant 
mechanism for cellmediated LDL modification. Free Radic. Biol. Med. 34:1271– 82. 
 
Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H. 1997 Dietary soybean protein 
increases insulin receptor gene expression in Wistar Fatty rats when dietary polyunsaturated 
fatty acid level is low. J. Nutr. 127: 1077-1083      
 
 
 
 
60
Jacobsen BK, Knutsen SF, Fraser GE. 1998 Does high soy milk intake reduce prostate cancer 
incidence? The Adventist Health Study (United States). Cancer Causes Control. 9(6): 553–
557. 
 
Jenkins DJ, Kendall CW, Garsetti M, et al. 2000a Effect of soy protein foods on low-density 
lipoprotein oxidation and ex vivo sex hormone receptor activity—a controlled crossover trial. 
Metabolism 49:537–43. 
 
Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D, Vidgen E, 
Cunnane SC, Leiter LA, Josse RG. 2002 Effects of high- and low-isoflavone soyfoods on 
blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and 
women. Am J Clin Nutr. 76(2):365-72.  
Jenkins DJ, Kendall CW, Vidgen E, Vuksan V, Jackson CJ, Augustin LS, Lee B, Garsetti M 
& Agarwal S, et al. 2000b Effect of soy-based breakfast cereal on blood lipids and oxidized 
low-density lipoprotein. Metabolism 49:1496-1500. 
 
Jha HC, Von Recklinghausen G, Zilliken F. 1985 Inhibition of in vitro microsomal lipid 
peroxidation by isoflavonoids. Biochem. Pharmacol. 34:1367–1369. 
 
Jiang F, Jones GT, Husband AJ, Dusting GJ. 2003 Cardiovascular Protective Effects of 
Synthetic Isoflavone Derivatives in Apolipoprotein E-Deficient Mice. J. Vasc. Res. 40:276-
284.    
 
Kao YC, Zhou C, Sherman M, Laughton C.A and Chen, S. 1998 Molecular basis of the 
inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone 
phytoestrogens: a site-directed mutagenesis study. Environ. Health Perspect. 106, pp. 85–92. 
 
Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME, Arjmandi BH. 2002 Soy protein 
supplementation increases serum insulin-like growth factor-I in young and old men but does 
not affect markers of bone metabolism. J. Nutr. 132, pp. 2605–2608. 
 
 
 
61
 
Khosla P, Samman S, Carroll KK. 1991 Decreased receptor-mediated LDL catabolism in 
casein-fed rabbits precedes the increase in plasma cholesterol levels. J. Nutr. Biochem. 
2:203–9.   
 
Kim S, Shin HJ, Kim SY, Kim JH, Lee YS, Kim DH, and Lee MO. Genistein enhances 
expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol. 
Cell Endocrinol. 220: 51–58, 2004.  
 
King RA. 1998 Daidzein conjugates are more bioavailable than genistein conjugates in rats. 
Am. J. Clin. Nutr. 68(suppl): 1496S-1499S.  
 
Kinjo J, Tsuchihashi R, Morito K, Hirose T, Aomori T, Nagao T, Okabe H, Nohara T, Kirk, 
E. A., Sutherland, P., Wang, S. A., Chait, A. & LeBoeuf, R. 1998 Dietary isoflavones reduce 
plasma cholesterol and atherosclerosis in C57BL/6J mice but not LDL receptor-deficient 
mice. J. Nutr. 128:954-959.  
 
Kovanen PT, Brown MS, Goldstein JL. 1979 Increased binding of lowdensity lipoprotein to 
liver membrane from rats treated with 17 alpha-ethinyl estradiol. J. Biol. Chem.254:1367–73. 
 
Lavigne C, Marette A, Jacques H. 2000 Cod and soy proteins compared with casein improve 
glucose tolerance and insulin sensitivity in rats. Endocrinology and Metabolism 278: E491-
E500. 
 
Lee S-O, Renouf M, Ye Z, Hendrich S & Murphy PA. 2005a The isoflavone glycitein 
lowered plasma cholesterol in female Golden Syrian Hamsters. Ph.D. Dissertation, Iowa 
State University Library, Ames, IA 
 
 
 
 
62
Lee S-O, Simons AL, Murphy PA & Hendrich S. 2005b Soyasaponins Lowered Plasma 
Cholesterol and Increased Fecal Bile Acids in Female Golden Syrian Hamsters. Experimental 
Biology and Medicine 230:472-478.      
 
Leinonen M, Saikku P. 2002 Evidence for infectious agents in cardiovascular disease and 
atherosclerosis. Lancet Infect Dis 2:11–17.  
 
Levy JR, Faber KA, Ayyash L, Hughes CL Jr. 1995 The effect of prenatal exposure to the 
phytoestrogen genistein on sexual differentiation in rats. Proc. Soc. Exp. Biol. Med. 
208(1):60-6.     
 
Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. 2005 Inactivation of nuclear factor 
B by soy isoflavone genistein contributes to increased apoptosis induced by 
chemotherapeutic agents in human cancer cells. Cancer Res. 65:6934 42.     
     
Li Y, Bhuiyan M, Sarkar FH. 1999 Induction of apoptosis and inhibition of c-erbB-2 in 
MDA-MB-435 cells by genistein. Int. J. Oncol. 15(3): 525–533. 
 
Li Y, Sarkar H 2002  Inhibition of NF-kB activation in PC3 cells by genistein is mediated via 
Akt signaling pathway. Clin. Cancer Res. 8(7): 2369–2317. 
 
Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. 1998 Genistein-induced G2-M 
arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. 
Cancer 31(3): 184–191. 
 
Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, 
Ausman LM. 2002 Lipoprotein response to diets high in soy or animal protein with and 
without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb. Vasc. 
Biol. 22:1852–1858. 
 
 
 
 
63
Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson J-A, Ohlsson C. 
2003 Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a 
“ying yang” relationship between ERalpha and ERbeta in mice. Mol. Endocrinol. 17, pp. 
203–208.  
 
Lissin LW, Oka R, Lakshmi S, Cooke JP. 2004 Isoflavones improve vascular reactivity in 
postmenopausal women with hypercholesterolemia. Vasc Med. 9:26-30.  
 
Liu Z, Li W, Sun J, Liu C, Zeng Q, Huang J, Yu B, Huo J. 2004  Intake of soy foods and soy 
isoflavones by rural adult women in China. Asia Pac J Clin Nutr 13:204–209.  
 
Lovati MR, Manzoni C, Canavesi A, Sirtori M, Vaccarino V, Marchi M, Gaddi G & Sirtori 
CR. 1987 Soybean protein diet increases low density lipoprotein receptor activity in 
mononuclear cells from hypercholesterolemic patients. J Clin. Investig. 80:1498-1502.  
 
Lucas EA, Khalil DA, Daggy BP, Arjmandi BH. 2001 Ethanol-extracted soy protein isolate 
does not modulate serum cholesterol in golden Syrian hamsters: a model of postmenopausal 
hypercholesterolemia. J. Nutr. 131:211-214.                
   
Lucas EA, Lightfoot SA, Hammond LJ, Devareddy L, Khalil DA, Daggy BP, Soung do Y, 
Arjmandi BH. 2003 Soy isoflavones prevent ovariectomy-induced atherosclerotic lesions in 
Golden Syrian hamster model of postmenopausal hyperlipidemia.  Menopause. 10(4):314-21. 
 
Lukaczer D, Darland G, Tripp M, Liska D, Lerman RH, Schiltz B, Bland JS. 2005 Clinical 
effects of a proprietary combination isoflavone nutritional supplement in menopausal 
women: a pilot trial. Altern Ther Health Med. 11(5):60-5.  
 
Magana MM, Koo S, Towle HC & Osborne TF. 2000 Different sterol regulatory element-
binding protein-1 isoforms utilize distinct co-regulatory factors to activate the protmoter for 
fatty acid synthase. J. Biol. Chem. 275:4726-4733.  
 
 
 
64
 
Mahn K, Borras C, Knock GA, Taylor P, Khan IY, Sugden D, Poston L, Ward JP, Sharpe 
RM, Vina J, Aaronson PI & Mann GE. 2005 Dietary soy isoflavone-induced increases in 
antioxidant and eNOS gene expression lead to improved endothelial function and reduced 
blood pressure in vivo. FASEB J 19, 1755–1757. 
 
Malinow MR. 1994 Homocyst(e)ine and arterial occlusive diseases. J. Intern. Med. 236:603-
617. 
 
Masamune Y. 2004 Interactions of phytoestrogens with estrogen receptors alpha and beta 
(III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from 
human urine. Biol Pharm Bull 27:185–188. 
 
McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. 2004 Osteoporosis and 
cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23, pp. 1–
10. 
 
Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. 1992 Perspective: how many 
women have osteoporosis? J. Bone Miner. Res. 7: 1005-1010. 
 
Mendez MA, Anthony MS, Arab L. 2002 Soy-based formulae and infant growth and 
development: a review. J. Nutr. 132(8):2127-30. 
 
Merz-Demlow BE, Duncan A M, Wangen KE, Xu X, Carr TP, Phipps WR & Kurzer MS. 
2000 Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal 
women. Am. J. Clin. Nutr. 71:1462-1469. 
 
Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, and Shay N. 2003 Soy isoflavones 
exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats 
and murine RAW 264.7 cells. J Nutr 133: 1238–1243.  
 
 
 
65
 
Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF. 2006 Dietary isoflavone supplementation 
modulates lipid metabolism via PPAR {alpha}-dependent and -independent mechanisms. 
Physiol. Genomics 26: 8-14. 
 
Miller WR, Anderson TJ and Jack WJ. 1990 Relationship between tumour aromatase 
activity, tumour characteristics and response to therapy. J. Steroid Biochem. Mol. Biol. 37. 
pp. 1055–1059. 
 
Millinder-Vallett S, Sanchez HB, Rosenfeld JM. & Osborne TF. 1996 A direct role for Sterol 
regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl Coenzyme A 
reductase gene. J. Biol. Chem. 271:12247-12253. 
 
Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC. 2003 Estrogen 
receptor isoform-specific regulation of endogenous gene expression in human osteoblastic 
cell lines expressing either ERalpha or ERbeta. J. Cell Biochem. 90, pp. 315–326.  
 
Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Squadrito F. 
2002 Effects of genistein and hormone-replacement therapy on bone loss in early 
postmenopausal women: A randomized double-blind placebo-controlled study. Journal of 
Bone and Mineral Research, 17 (10), pp. 1904-1912. 
 
Mullen E, Brown RM, Osborne TF, and and Shay NF. 2004 Soy isoflavones affect sterol 
regulatory element binding proteins (SREBPs) and SREBP regulated genes in HepG2 cells. 
J. Nutr. 134: 2942–2947. 
 
Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. 2003 Soy product intake 
is inversely associated with serum homocysteine level in premenopausal Japanese women. J 
Nutr. 133(3):797-800.  
 
 
 
 
66
Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A & Abbey 
M. 1997 Soy isoflavones improve systemic arterial compliance but not plasma lipids in 
menopausal and perimenopausal women. Arterioscler. Thromb. Vasc. Biol. 17:3392-3398.  
 
Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A & Abbey 
M. 1997 Soy isoflavones improve systemic arterial compliance but not plasma lipids in 
menopausal and perimenopausal women. Arterioscler. Thromb. Vasc. Biol. 17:3392-3398. 
 
Nevala R, Vaskonen T, Vehniainen J, Korpela R & Vapaatalo H. 2000 Soy based diet 
attenuates the development of hypertension when compared to casein based diet in 
spontaneously hypertensive rat. Life Sci 66:115-124. 
 
Onozawa M, Kawamori, T, Baba M, Fukuda K, Toda T, Sato H, Ohtani M, Akaza H, 
Sugimura T, Wakabayashi K. 1999 Effects of a soybean isoflavone mixture on 
carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J. Cancer Res. 90(4): 393–
398. 
Park E, Shin JI, Park OJ, Kang MH. 2005 Soy isoflavone supplementation alleviates 
oxidative stress and improves systolic blood pressure in male spontaneously hypertensive 
rats. J Nutr Sci Vitaminol (Tokyo). 51(4):254-9.  
 
Pelissero C, Lenczowski MJ, Chinzi D, Davail-Cuisset B, Sumpter JP and Fostier A. 1996 
Effects of flavonoids on aromatase activity, an in vitro study, J. Steroid Biochem. Mol. Biol. 
57. pp. 215–223. 
 
Pockley AG. 2002 Heat shock proteins, inflammation, and cardiovascular disease. 
Circulation 105:1012–1017.   
 
Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman Jr JW. 1998 Soy protein and 
isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. 
Clin. Nutr. 68, pp. 1375S–1379S. 
 
 
 
67
  
Potter SM. 1995 Overview of proposed mechanisms for the hypocholesterolemic effect of 
soy. J. Nutr. 125:606S-611S.  
 
Raines EW & Ross R. 1995 Biology of atherosclerotic plaque formation: possible role of 
growth factors in lesion development and the potential impact of soy. J. Nutr. 125(suppl. 
3):624S-630S. 
 
Reaven G, Abbasi F, McLaughlin T. 2004 Obesity insulin resistance, and cardiovascular 
disease. Recent Prog. Horm. Res. 59: 207-223. 
 
Renouf M, Lee S-O, Hendrich S. 2006 Isoflavone excretion phenotypes influence plasma 
cholesterol in golden Syrian hamsters.  Nutr. Res. 26:77-83.  
 
Renouf M. 2005 Ph.D. Dissertation, Iowa State University Library, Ames, IA 
 
Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. 2006 A meta-analysis of the 
effect of soy protein supplementation on serum lipids. Am. J. Cardiol. 98(5):633-40. 
 
Rickert DA, Meyer MA, Hu J, Murphy PA. 2004 Effect of extraction pH and temperature on 
isoflavone and saponin partitioning and profile during soy protein isolate production. J. Food 
Sci. 69:C623-631.  
 
Rivas M, Garay RP, Escanero JF, Cia P Jr, Cia P & Alda JO. 2002 Soy milk lowers blood 
pressure in men and women with mild to moderate essential hypertension. J. Nutr. 132:1900-
1902. 
 
Rodrigues HG, Diniz YS, Faine LA, Galhardi CM, Burneiko C, Almeida JA, Ribas BO, 
Novelli ELB. 2005 Antioxidant effect of saponin: potential action of a soybean flavonoid on 
 
 
 
68
glucose tolerance and risk factors for atherosclerosis. International Journal of Food Sciences 
and Nutrition, Volume 56, Number 2, March; 79-85(7). 
         
Rosier Olimpio Pereira I, Saes Parra Abdalla D. 2006 Soy isoflavones reduce heat shock 
proteins in experimental atherosclerosis.  Eur. J. Nutr. Apr; 45(3):178-86. 
 
Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. 2006 
American Heart Assocation Nutrition Committee. Soy protein, isoflavones, and 
cardiovascular health: an American Heart Association science advisory for professionals 
from the Nutrition Committee. Circulation. 113: 1034–1044. 
 
Schachinger V, Britten MB, and Zeiher AM. 2000 Prognostic impact of coronary vasodilator 
dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899-
1906. 
 
Schneider H and Blaut M. 2002 Anaerobic degradation of flavonoids by Eubacterium 
ramulus. Arch. Microbiol. 173: 71–75.  
 
Schoefer L, Mohan R, Braune A, Birringer M, Blaut M. 2002 Anaerobic Cring cleavage of 
genistein and daidzein by Eubacterium ramulus. FEMS Microbiol. Lett. 208:197–202.  
 
Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. 1997 Exposure of infants to phyto-
oestrogens from soy-based infant formula. Lancet. 5;350(9070):23-7. 
 
Setchell KDR, Faughan MS, Avades T, Zimmer-Nechemias L, Brown NM, Wolfe BE, 
Brashear WT, Desai P, Oldfield MF, Botting NP, Cassidy A. 2003 Comparing the 
pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in 
premenopausal women. Am. J. Clin. Nutr. 77: 411-419. 
 
 
 
 
69
Sfakianos J, Coward L, Kirk M, Barnes S. 1997 Intestinal uptake and biliary excretion of the 
isoflavone genistein in rats. J. Nutr. 127: 1260-1268. 
 
Song TT, Lee SO, Murphy PA & Hendrich S. 2003 Soy protein with or without isoflavones, 
soy germ and soy germ extract, and daidzein lessen plasma cholesterol levels in golden 
Syrian hamsters. Exp. Biol. Med. 228:1063-1068. 
 
Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, D’Anna R, 
Corrado F, Ruggeri P, Frisina N, Squadrito G. 2003 Effect of genistein on endothelial 
function in postmenopausal women: a randomized, double-blind, controlled study. Am. J. 
Med. 114(6):470-476. 
 
Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA, Stallings VA, 
Drulis JM, Nelson SE, Hanson SA. 2001 Exposure to soy-based formula in infancy and 
endocrinological and reproductive outcomes in young adulthood. J. Am. Med. Assoc. 
286(7):807-14.  
 
Sugano M, Goto S, Yamada Y, Yoshida K, Hashimoto Y, Matsuo T, Kimoto M. 1990 
Cholesterol-lowering activity of various undigested fractions of soybean protein in rats. J. 
Nutr. 120, 977-985.   
 
Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, 
Hernandez L, et al. 2003 Phase I pharmacokinetic and pharmacodynamic analysis of 
unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol. 
Biomarkers Prev. 12:1213–21. 
 
Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S & McGrath BP. 2001 Dietary soy 
has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study 
in men and postmenopausal women. J. Clin. Endocrinol. Metab. 86:3053-3060. 
 
 
 
 
70
Tikkanen MJ, Wahala K, Ojala S, Vihma V & Adlercreutz H. 1998 Effect of soybean 
phytoestrogen intake on low density lipoprotein oxidation resistance. Proc. Natl. Acad. Sci. 
U.S.A. 95:3106-3110. 
 
Tontonoz P, Kim JB, Graves RA & Spiegelman B. M. 1993 ADD1: a novel helix-loop-helix 
transcription factor associated with adipocyte determination and differentiation. Mol. Cell. 
Biol. 13:4753-4759. 
 
Tsai J-C, Perrella MA, Yoshizumi M, et al. 1994 Promotion of vascular smooth muscle cell 
growth by homocysteine: a link to atherosclerosis. Proc. Natl. Acad. Sci. U S A. 91:6369-
6373. 
 
Tsangalis D, Ashton JF, McGill AEJ, Shah NP. Enzymic transformation of isoflavone 
phytoestrogens in soymilk by B–glucosidase-producing Bifidobacteria. J Food Sci 67:3104–
3113, 2002.  
 
Uehara M, Ohta A, Sakai K, Suzuki K, Watanabe S, Adlercreutz H. 2001 Dietary 
fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and 
daidzein and affect their urinary excretion and kinetics in blood of rats. J. Nutr. 131: 787-
795.  
 
Ueno T, Uchiyama S, Kikuchi N. 2002 The role of intestinal bacteria on biological effects of 
soy isoflavones in humans. J. Nutr. 132:594S. 
 
Van der Schouw YT, Pijpe A, Lebrun CE, Bots ML, Peeters PH, van Staveren WA, 
Lamberts SW & Grobbee DE. 2002 Higher usual dietary intake of phytoestrogens is 
associated with lower aortic stiffness in postmenopausal women. Arterioscler. Thromb. Vasc. 
Biol. 22:1316-1322. 
 
 
 
 
71
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp, D., and Miyamoto, S. 1995 Rel/NF-
kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 9(22): 
2723–2735. 
 
Viereck V, Grundker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC. 2002 
Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular 
osteoblasts. J. Cell Biochem. 84, pp. 725–735. 
 
Wagner JD, Schwenke DC, Greaves KA, Zhang L, Anthony MS, Blair RM, Shadoan MK, 
Williams JK. Soy protein with isoflavones, but not an isoflavone-rich supplement, improves 
arterial low-density lipoprotein metabolism and atherogenesis. Arteroscler Thromb Vasc 
Biol. 2003;23:2241-2246.  
 
Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM & Chowienczyk PJ. 2001 The 
phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm 
vasculature with similar potency to 17ß-estradiol. Circulation 103:258-262. 
 
Wang H-J, Murphy PA. 1994 Isoflavone composition of American and Japanese soybeans in 
Iowa: effects of variety, crop year and location. J. Agric. Food Chem. 42: 1674-1677. 
 
Wang H-J, Murphy PA. 1996 Mass balance study of isoflavones during soybean processing. 
J. Agric. Food chem. 44: 2377-2383. 
 
Wangen KE, Duncan AM, Xu  X & Kurzer MS. 2001 Soy isoflavones improve plasma lipids 
in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am. J. 
Clin. Nutr. 73:225-231. 
 
Wangen KE, Duncan AM, Xu X, Kurzer MS. 2001 Soy isoflavones improve plasma lipids in 
normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin 
Nutr. 73:225–231. 
 
 
 
72
 
Washburn S, Burke GL, Morgan T, Anthony M. 1999 Effect of soy protein supplementation 
on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. 
Menopause 6:7-13. 
 
Weggemans RM, Trautwein EA. 2003 Relation between soy-associated isoflavones and LDL 
and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr. 57:940–
946.  
 
Wei H, Bowen R, Cai Q, Barnes S, Wang Y. 1995 Antioxidant and antipromotional effects 
of the soybean isoflavone genistein. Proc Soc Exper Biol Med 208:124-130 
 
Wilcox JN, Blumenthal BF. 1995 Thrombotic mechanisms in atherosclerosis: potential 
impact of soy proteins. J. Nutr. 125(suppl. 3):631S-638S.  
 
Wiseman H, O’Reilly JD, Adlercreutz H, Mallet AI, Bowey EA, Rowland IR & Sanders TA. 
2000 Isoflavone phytoestrogens consumed in soy decrease F (2)-isoprostane concentrations 
and increase resistance of low-density lipoprotein to oxidation in humans. Am. J. Clin. Nutr. 
72:395-400. 
 
Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC & Pownell HJ. 1998 Cholesterol-
lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Am. 
J. Clin. Nutr. 68(suppl. 6):1385S-1389S. 
 
Xu X, Duncan AM, Wangen KE, Kurzer MS. 2000a Soy consumption alters estrogen 
metabolism in post-menopausal women. Cancer Epidemiol. Biomarkers Prevention 9: 781-
786. 
 
Xu X, Harris KS, Wang H-J, Murphy PA, Hendrich S. 1995 Bioavailability of soybean 
isoflavones depends upon the gut microflora in women. J. Nutr. 125: 2307-2315. 
 
 
 
73
 
Xu X, Wang HJ, Murphy PA, Cook L & Hendrich S. 1994 Daidzein is a more bioavailable 
soymilk isoflavone than is genistein in adult women. J. Nutr. 124:825-832. 
 
Xu X, Wang H-J, Murphy PA, Hendrich S. 2000b Neither background diet nor type of soy 
food affects short-term isoflavone bioavailability in women. J. Nutr. 130: 798-801. 
 
Yamakoshi J, Piskula MK, Izumi T, Tobe K, Saito M, Kataoka S, Obata A, Kikuchi M. 2000 
Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development 
in cholesterol-fed rabbits. J. Nutr. 130:1887-1893. 
 
Yamakoshi J, Piskula MK, Izumi T, Tobe K, Saito M, Kataoka S, Obata A, Kikuchi M. 2000 
Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development 
in cholesterol-fed rabbits. J Nutr. 130:1887-1893. 
 
Yang D, Feletou M, Levens N, Zhang JN, and Vanhoutte PM. 2003 A diffusible substance(s) 
mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 41: 143-
148. 
Yannai S, Day,AJ, Williamson, G and Rhodes, M.J. 1998 Characterization of flavonoids as 
monofunctional or bifunctional inducers of quinone reductase in murine hepatoma cell lines, 
Food Chem. Toxicol. 36 pp. 623–630.  
 
Yellayi S, Naaz A, Szewczykowski MA, Sato T, Woods JA, Chang J, Segre M, Allred CD, 
Helferich WG, Cooke PS. 2002 The phytoestrogen genistein induces thymic and immune 
changes: a human health concern. PNAS 99: 7616-7621.  
 
Yildirir A, Tokgozoglu SL, Oduncu T, Oto A, Haznedaroglu I, Akinci D, Koksal G, Sade E, 
Kirazli S & Kes S. 2001 Soy protein diet significantly improves endothelial function and 
lipid parameters. Clin. Cardiol. 24:711-716. 
 
 
 
 
74
Yousef MI, Kamel KI, Esmail AM, Baghdadi HH. 2004 Antioxidant activities and lipid 
lowering effects of isoflavone in male rabbits. Food Chem. Toxicol. 42(9):1497-503. 
 
Zhang X, Shu XO, Gao Y-T, Yang G, Li Q, Li H, Jin F, Zheng W. 2003 Soy food 
consumption is associated with lower risk of coronary heart disease in Chinese women. J 
Nutr. 133:2874-2878. 
 
Zhang Y, Song TT, Murphy PA, Hendrich S. 1999a Daidzein and genistein glucuronides in 
vitro are weakly estrogenic and activate human natural killer cells in nutritionally relevant 
concentrations. J. Nutr. 129: 399-405. Erratum J. Nutr. 2001,131: 147-148. 
 
Zhang Y, Wang G-J, Song TT, Murphy PA and Hendrich S. 1999 Urinary disposition of the 
soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate 
fecal isoflavone degradation activity. J. Nutr. 129: 957-962. Erratum J. Nutr. (2001) 131: 
147-148.  
 
Zhang Y, Wang G-J, Song TT, Murphy PA, Hendrich S. 1999b Urinary disposition of the 
soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate 
fecal isoflavone activity. J. Nutr. 129: 957-962. 
 
Zhang Y. 2000 Dissertation, Iowa State University Library, Ames, IA. 
 
Zheng Y, Hu J, Murphy PA, Alekel DL, Franke WD & Hendrich S. 2003 Rapid Gut Transit 
Time and Slow Fecal Isoflavone Disappearance Phenotype Are Associated with Greater 
Genistein Bioavailability in Women. J. Nutr. 133:3110-3116. 
 
Zheng Y, Lee S-O, Verbruggen MA, Murphy PA, Hendrich S. 2004 The apparent 
absorptions of isoflavone glucosides and aglucons are similar in women and are increased by 
rapid gut transit time and low fecal isoflavone degradation. J. Nutr. 134: 2534-2539. 
 
 
 
 
75
Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S. 1996 Aromatase gene 
expression and its exon I usage in human breast tumors. Detection of aromatase messenger 
RNA by reverse transcription-polymerase chain reaction. J. Steroid Biochem. Mol. Biol. 
59(2):163-71.           
 
Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. 1999 Soybean 
phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor 
angiogenesis in mice. J. Nutr. 129(9): 1628–1635. 
 
Zhuo XG, Melby MK, and Watanabe S. 2004 Soy isoflavone intake lowers serum LDL 
cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J. Nutr. 134: 2395–
2400.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76
HIGH URINARY ISOFLAVONE EXCRETION PHENOTYPE DECREASES 
PLASMA CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS FED SOY PROTEIN 
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                                                       Abstract 
          Apparent absorption of isoflavones varies greatly among individuals, but is 
relatively stable within an individual. We hypothesized that high urinary isoflavone excreters 
would show less plasma non-HDL cholesterol than low isoflavone excreters after soy protein 
feeding. Fifty Golden Syrian hamsters were fed a high fat/casein diet (n = 10) or a high 
fat/soy protein diet (n = 40) for 4 wk. Two distinct urinary isoflavone excretion phenotypes 
were identified based upon HPLC analysis of urinary glycitein using a pairwise correlation 
plots analysis, or based upon total urinary isoflavone using a hierarchical cluster test. High 
isoflavone excreters showed significantly greater urinary isoflavones (p<0.05) than did low 
isoflavone excreters at w 1 and 4. The low urinary glycitein excretion phenotype was more 
stable than the high urinary glycitein excretion phenotype by McNemar’s test. High urinary 
isoflavone excreters had significantly less non-HDL cholesterol than did the low isoflavone 
excreters or casein-fed controls (p < 0.05). Plasma total and non-HDL cholesterol were 
significantly negatively correlated with urinary daidzein, glycitein and total isoflavone 
excretion (r between -0.45 and -0.58, p<0.05). Urinary isoflavone excretion phenotypes 
predicted the cholesterol-lowering efficacy of soy protein.  Isoflavone absorbability, probably 
due to gut microbial ecology, is an important controllable variable in studies of effects of soy 
protein on blood lipids.  
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                                                            Introduction 
        Increased intake of soy protein lowers blood cholesterol, as confirmed by a 
recent meta-analysis of 22 randomized human trials (1).  The role of isoflavones in this effect 
of soy protein was determined to be negligible. But, moderately hypercholesterolemic men 
and women who ate 62 mg total isoflavones/d in soy protein had decreased total and LDL 
cholesterol (LDL-C) compared with casein-fed controls (2). LDL-C was less in 
premenopausal women who ate soy protein high in isoflavones diet compared with controls 
during the midfollicular and periovulatory phases of the menstrual cycle (3). These same soy 
foods and doses fed to postmenopausal women in a crossover study showed that only the 
greatest isoflavone intake caused significantly less LDL-C compared with controls (4). A 
minimal dose of 96 mg isoflavone/d was required for cholesterol-lowering in a meta-analysis 
of 8 human studies with no, low and high-isoflavone containing soy protein treatments (5).   
    The hamster model has also provided contrasting results across studies of 
isoflavones.  Song et al. (2003) (6) fed male and female Golden Syrian hamsters 
(n=10/sex/group; 6-8 weeks of age). Total cholesterol and non-HDL cholesterol were 
significantly less in hamsters fed soy protein with or without isoflavones or fed 1.3 mmol 
daidzein/kg diet in a casein-based diet (~ content of total isoflavones in a 25% soy protein 
diet), compared with a high fat/casein control diet, illustrating similar efficacy for cholesterol 
lowering by soy protein and daidzein.  The cholesterol-lowering effects of isoflavones 
increased with increasing isoflavone doses in six mo-old ovariectomized Golden Syrian 
hamsters (7). In another study, plasma isoflavones were positively correlated with plasma 
LDL+VLDL-C in female hamsters, and males fed isoflavones in a casein/lactalbumin diet 
showed no cholesterol-lowering compared with the control diet, but isoflavones within a soy 
diet increased cholesterol-lowering (8). The addition of lactalbumin to casein seemed to alter 
the effects of isoflavones on blood lipids. 
                     Interindividual variability in apparent absorption of isoflavones may account for 
the observed negligible effects of isoflavones in meta-analyses of soy protein feeding trials 
(1).  In a randomized crossover design, seven women fed various doses of soy milk showed 
distinct patterns of urinary isoflavone excretion:  two women had significantly greater 
excretion of isoflavones than did the other five women (9). Human fecal isoflavone 
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disappearance phenotypes were observed in vitro (10).  The phenotypes were stable in 12 of 
15 subjects reexamined after 10 months, and fecal isoflavone disappearance was strongly 
inversely correlated with plasma isoflavones in 8 men fed a single isoflavone dose (10). Gut 
microbes seemed played an important role in the metabolism of isoflavones. Zheng et al. (11) 
identified fecal isoflavone disappearance phenotypes among 35 Chinese and 33 Caucasian 
women.  The high urinary isoflavone excretion phenotype affected urinary excretion of 
genistein when accompanied by relatively rapid gut transit time.  Low fecal isoflavone 
degradation rate in 12 women fed soy for 7 days was related to ~50% greater apparent 
absorption of isoflavones compared with 13 women with high fecal isoflavone degradation 
rates (12).  
                         Golden Syrian hamsters may be good models to study the role of isoflavone 
bioavailability in the cholesterol-lowering efficacy of isoflavones because greater isoflavone 
bioavailability was associated with increased cholesterol-lowering by these compounds when 
isoflavones were fed in a casein-based diet (13). Interindividual variability in isoflavone 
bioavailability, which we think is a significant issue in understanding the health effects of 
these compounds in humans, seemed to be greater among female than among male hamsters 
(13), making female hamsters a particularly useful model for humans.  The objectives of this 
study were to identify in a hamster model urinary isoflavone excretion phenotypes using 
statistical methods and to test the hypothesis that a high excreter isoflavone bioavailability 
phenotype was associated with cholesterol-lowering efficacy of dietary soy protein.  
                                  
                                      Materials and Methods 
 
Diets 
In the experimental period, hamsters were fed a hyperlipidemic casein-based control 
diet high in saturated fatty acids (14) or a treatment diet with soy protein (Supro 670®, 
Protein Technologies International, St. Louis, MO) substituted for casein. The isoflavone 
content of soy protein was analyzed by HPLC linear gradient with UV detection (15). The 
soy protein contained 405 µg of daidzein, 647 µg of genistein, and 72 µg of glycitein/g. The 
saponin fractions of soy protein were analyzed by HPLC (16); the soy diet contained 1.2 mg 
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saponin/g. Experimental diets were prepared and stored at 4°C. Food intake was measured 
weekly and over 2-3 consecutive days in metabolic cages.  
 
          Animals and Sample Collection 
          Fifty 8 wk old female golden Syrian hamsters, 118-128 g were obtained from Charles 
River Breeding Laboratories (St. Constant, Canada). Hamsters were fed AIN 93 M diet for 2 
mo (17), then assigned to two groups randomly but to achieve similar mean body 
weight/group: 10 hamsters fed casein diet and 40 hamsters fed soy protein diet. The hamsters 
had free access to food and drinking water in a temperature-controlled room (23°C) with a 12 
h light/dark cycle during the 4-week experimental period. Clinical observation and body 
weight measurements were conducted once a week. Urinary and fecal samples were collected 
over 24 h at the end of weeks 1 and 4 when hamsters were put in metabolic cages 
individually for 2-3 d.  At the end of the feeding period, diets were withdrawn from hamsters 
14-16 h before they were euthanized under CO2. Blood samples were collected by cardiac 
puncture in EDTA tubes and centrifuged at 5000g for 10 min, 4°C.  Plasma samples were 
then frozen at -20°C until analysis. The animal experimental protocol was approved by the 
Iowa State University Animal Use Committee. 
 
Plasma Lipid Analysis 
Plasma total cholesterol, HDL cholesterol, and triglyceride concentrations were 
measured with Infinity TM Cholesterol and Triglycerides Reagent (Thermo DMA, Inc. 
Louisville, CO) and HDL Cholesterol Reagent (PTA/MgCl2) Diagnostics kits (Sigma 
Diagnostics, Inc., St. Louis, MO). Non-HDL cholesterol was calculated by subtracting HDL 
cholesterol from total cholesterol and represented LDL+ID+VLDL cholesterol. 
 
Chemicals 
 Daidzein (4′,7-dihydroxyisoflavone), genistein (4′,5,7-trihydroxyisoflavone), 
glycitein (4′,7-dihydroxy-6-methoxyisoflavone), and THB (2,4,4′-trihydroxybenzoin) were 
synthesized (18). Milli-Q (Millipore Co., Bedford, MA) HPLC grade water was used. Other 
HPLC solvents were purchased from Fisher Scientific Co. (Pittsburgh, PA).      
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Analytical Methods 
Fecal and urinary sample preparation and HPLC analysis 
Isoflavone extraction from urine and fecal samples was performed as described 
previously (19). Fecal saponin metabolite analysis in wk 4 samples was as described (16, 20). 
 
Statistical Analysis
            A pairwise correlation plots analysis and hierarchical clustering test were conducted 
to classify isoflavone excretion phenotypes. One-way ANOVA followed by t-tests 
determined the differences in urinary and fecal isoflavones between two isoflavone excretion 
phenotypes at weeks 1 and 4, differences in excretion of daidzein, genistein and glycitein 
within excretion phenotype, differences in the plasma lipid levels between the soy protein-
fed and control groups, between isoflavone excretion phenotypes, and between isoflavone 
excretion phenotypes and the controls. McNemar’s test (21) was used to verify high and low 
isoflavone phenotype stability. Intraclass Correlation Analysis (22) was done to verify 
individual phenotype stability. Pearson correlation analysis determined the correlations 
between urinary and fecal isoflavone excretion and between isoflavone excretion and plasma 
lipids. All results were reported as mean ± SEM.  All differences were considered significant 
at P < 0.05. Statistical analysis was performed with R software (23) and SAS (SAS Institute, 
version 8.1; 1998, Cary, NC). 
 
                                                  Results 
 
Identification of Urinary Isoflavone Excretion Phenotypes 
Food intakes and body weights did not differ between the groups at w 1 and 4.  For 
casein-fed hamsters, food intake was 7.7 ± 0.5 g/d (wk 1) and 7.1 ± 0.6 g/d (wk 4), whereas 
soy protein-fed hamsters had food intakes of 7.1 ± 0.6 and 7.0 ± 0.5 g/d (means ± SEM) at 
wk 1 and 4, respectively.  Body weights for both groups (means ± SEM) were 123 ± 3 g 
initially; casein-fed hamsters had body weights of 130 ± 5 g (wk 1) and 134 ± 7 g (wk 4), 
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whereas soy protein-fed hamsters had body weights of  128 ± 6 g (wk 1) and 131 ± 6 g (wk 
4).  
    Urinary isoflavone excretion phenotypes were classified on pairwise correlation 
plots. The plot of the ranked values showed a gap in urinary glycitein excretion between 
individuals at w 1 (Fig. 1). From these rankings, hamster 2 had the maximum excretion of all 
isoflavones. Hamster 8 remained among the least in urinary excretion of all isoflavones. The 
highlighted data for these 2 individuals indicates the consistency of apparent absorption for 
all isoflavones, and the extreme difference among individuals.  The number of observations 
in the two categories were great enough for inference, thus the statistical analysis showed a 
natural cut-off for  ‘high’ and ‘low’ urinary glycitein excreters (Fig.1).    
     Another method to classify urinary isoflavone excretion phenotypes was based on 
hierarchical clustering using a complete linkage method (Fig. 2), which ensured that all items 
in a cluster were within some maximum distance of each other.  Only hamsters in two of the 
four groups were used in further studies (Group 3 – High isoflavone excreters, Group 2 – 
Low isoflavone excreters) because they displayed more consistent characteristics within a 
cluster than did the two other groups. Hamster 2 was removed from this analysis because it 
consistently formed its own ‘cluster’. Hamster 1 had missing values for the clustering 
variables (no HPLC data). The full clustering tree for 38 hamsters indicated 4 excretion 
phenotypic clusters (Fig.3). Bivariate plots showed each observation’s categorization with 
the respective phenotypic cluster number. We chose to compare Clusters 2 and 3 for the 
effect of isoflavone excretion on plasma lipids because Clusters 1 and 4 had no ‘universal’ 
ordering (i.e., individuals in Clusters 2 and 3 remained grouped for their excretion of each of 
the isoflavones and for total isoflavone excretion). We classified urinary isoflavone excretion 
phenotypes for w 4 by the same methods. 
 
Influence of Urinary Isoflavone Excretion Phenotypes on Isoflavone and 
Saponin Excretion 
            Glycitein excretion (as percentage of ingested dose) was significantly greater than 
daidzein and genistein excretion in urine within urinary excretion phenotype (p<0.05, Table 
1, 2).   
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According to high and low urinary glycitein excretion phenotypes identified by a 
natural break point, high excreters excreted significantly more urinary daidzein, genistein, 
glycitein and total isoflavone (p<0.05) than did individuals of the low excretion phenotype at 
wk 1 and 4 (Table 1). No differences were found in fecal daidzein, genistein, and total 
isoflavone excretion between excretion phenotypes at wk 1 and 4.   
According to total urinary isoflavone excretion at wk 1 (Fig. 2 and 3), high and low 
urinary excretion phenotypes were identified by a hierarchical cluster test. Individuals of the 
high excretion phenotype (cluster 3) excreted more urinary daidzein, genistein, glycitein and 
total isoflavone (p<0.05) than did those of the low urinary excretion phenotype (cluster 2) at 
wk 1 and 4 (Table 3).  
No differences were found in high and low fecal saponin metabolite (20) excretion 
phenotypes in wk 4 according to glycitein and total isoflavone phenotypes (data not shown).   
 
Stability of Urinary Excretion Phenotypes over 4 Weeks 
 McNemar’s test showed the stability of the urinary excretion phenotypes between w 
1 and 4 (Table 2, 3). Only 4 of 39 individuals switched their urinary glycitein excretion 
phenotypes between wk 1 and 4. Twenty-six hamsters remained low excreters and 1 hamster 
became a high excreter. The low urinary glycitein excretion phenotype was more stable than 
the high glycitein urinary excretion phenotype. Three of 11 hamsters of the high glycitein 
excreter phenotype became low excreters. By the other classification method, the low 
excretion phenotype (cluster 2) was more stable (2 individuals switched) than the high 
excretion phenotype (cluster 3) in which 3 individuals switched.  
             Individual glycitein excretion phenotype stability from wk 1 to 4 (Fig. 4) ) was 
investigated using Intraclass Correlation Analysis, defined as δB2/(δB2 +δ2), which compared 
the variability between hamsters to the total variability in the data. The 95% confidence 
interval estimate for this ratio was [0, 0.89]. This interval was wide due to high variability, or 
low precision, in the estimate of this ratio.  However, the variability of the values within a 
hamster can be seen as the length of the lines connecting the two measurements. In general, 
there was less change from wk 1 to 4 when a hamster had a relatively low original glycitein 
excretion phenotype. 
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Plasma Lipids and Urinary Isoflavone Excretion Phenotypes      
 Compared with the control diet, the soy protein diet significantly lessened plasma 
total cholesterol by 18% (p < 0.05), non-HDL cholesterol (non-HDL-C) by 30% (p<0.05) 
and non-HDL-C/HDL cholesterol (HDL-C) (p<0.05, Table 3). No significant differences in 
plasma HDL-C and triglyceride concentrations were found between groups. Plasma total 
cholesterol (by 26% v. 14%, p<0.05), non-HDL-C (by 51% v. 36%, respectively, p<0.05) 
and non- HDL-C/HDL-C (p<0.05) were significantly less in individuals of the high urinary 
glycitein excretion phenotype (identified at wk 1 or 4), compared with individuals of the low 
glycitein excretion phenotype (Table 3).  Individuals of the low glycitein excretion 
phenotype did not differ from hamsters fed the casein diet in plasma lipid status. Individuals 
of the high isoflavone excretion phenotype at either wk 1 or 4 had significantly less plasma 
total cholesterol (by 18% and 28%, respectively, p<0.05), non-HDL-C (by 49% and 53%, 
respectively, p<0.05) and the ratio of non- HDL-C to HDL-C (p<0.05) compared with 
individuals of the low isoflavone excretion phenotype (Table 3). Individuals of the low 
excretion phenotype were similar to casein controls in plasma lipid status. Isoflavone 
excretion phenotypes did not significantly affect plasma HDL-C and triglycerides. 
 
Relation between Plasma Lipids and Isoflavone or Saponin Metabolite Excretion 
 Strong relationships existed between urinary and fecal isoflavone excretion within 
individuals at wk 1 and 4 according to correlation analysis (r = 0.79-0.93, p<0.05). Total 
cholesterol level was significantly positively correlated with non-HDL-C and the ratios of 
non- HDL-C to HDL-C (r = 0.87 and 0.79, p<0.05). Non- HDL-C was significantly 
positively correlated with non-HDL-C/HDL-C (r=0.97, p<0.05). There was no correlation of 
HDL-C or triglyceride with total or non-HDL-C.              
               Total and non-HDL-C were significantly negatively correlated with urinary 
daidzein, glycitein and total isoflavone excretion (r = -0.45 to -0.58, p<0.05).  HDL-C and 
triglycerides were not significantly correlated with urinary or fecal isoflavone excretion. 
Total and non-HDL-C were not significantly correlated with fecal saponin metabolite 
excretion.    
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                                              Discussion 
         
  We identified two distinct urinary isoflavone excretion phenotypes based on urinary 
glycitein or total isoflavone excretion in hamsters using two statistical methods. Zheng et al. 
(12) showed that 13 women of a low in vitro fecal isoflavone disappearance phenotype and 
relatively rapid GTT showed ~50% greater urinary isoflavone excretion (apparent 
absorption) than did 12 women of a high fecal isoflavone disappearance phenotype and slow 
GTT when fed soy isoflavones for 7 days.  Hamsters showed in vitro cecal isoflavone 
degradation rate phenotypic clusters (24) that could account for the urinary isoflavone 
excretion phenotypes observed in the present study, and suggesting that the isoflavone 
bioavailability phenotypes observed in both humans (11, 12) and hamsters (13) are due to gut 
microbial degradation of isoflavones that differs greatly and relatively stably among 
individuals. 
         In hamsters, urinary isoflavone excretion was significantly greater than fecal 
isoflavone excretion, presumably due to gut microbial degradation of these compounds, as 
observed in humans (9, 25, Tables 2, 3).  Glycitein showed significantly greater excretion 
than daidzein or genistein in this study (Tables 2, 3), indicating its greater bioavailability than 
the other isoflavones. Feeding 1.18 or 1.77 mmol total isoflavones/kg diet to one-year old 
male (n = 10) and female (n=9) hamsters for 10 d produced similar 24-h urinary isoflavone 
excretion differences among the isoflavones (13). Daidzein was a more bioavailable 
isoflavone than genistein in women fed single doses of soymilk, as reflected in urinary 
excretion (9, 25).  Urinary glycitein excretion was similar to that of daidzein and greater than 
was genistein in 7 women and 7 men fed single doses of soymilk (19). Not all human studies 
have shown greater bioavailability for daidzein than for genistein.  Women who were “high 
excreters” of isoflavones did not differ in daidzein and genistein excretion, whereas “low 
excreters” showed greater daidzein than genistein excretion (9).  We also found that the low 
glycitein urinary excretion phenotype was more stable and the high glycitein urinary 
excretion phenotype was less stable in hamsters (Fig. 4).  In women, a high fecal daidzein 
isoflavone disappearance phenotype was not as stable as a low daidzein disappearance 
phenotype, but both high and low genistein disappearance phenotypes were relatively stable 
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(11).  Thus, in a broad sense, hamsters may usefully model human isoflavone bioavailability 
and its stable phenotypic variations, to better study the health effects of these compounds. 
           In the current study, either glycitein or total isoflavone bioavailability as 
reflected in urinary excretion clusters determined at wk 1 or 4 predicted cholesterol-lowering 
efficacy of soy protein (Table 3). Hamsters fed 1.3 mmol daidzein/kg diet for 10 weeks had 
lesser plasma cholesterol compared with casein-fed controls (20). In part because of the 
apparent similarity in daidzein and glycitein bioavailability in humans (19), the present 
results are likely to be relevant to humans for cholesterol-lowering efficacy of soy proteins 
containing isoflavones.  No studies of the effects of isoflavones on blood lipids have 
compared isoflavone bioavailability indices with cholesterol status to our knowledge, 
however Urban et al. (25) showed that serum isoflavones were increased as serum cholesterol 
was significantly decreased after isolated soy protein high in isoflavone content was eaten by 
34 elderly men for 6 weeks in a randomized crossover design that compared the high 
isoflavone soy protein to a soy protein that had omst of the isoflavones removed.  These 
subjects showed serum isoflavone concentrations after eating the soy protein high in 
isoflavones that varied among subjects more than tenfold for genistein and more than 
thirtyfold for daidzein.  This study along with several others (2-5) supported the role of 
isoflavones in cholesterol-lowering but did not attempt to relate individual isoflavone status 
to blood lipid status.  Based on our hamster model and the wide range of human variability in 
isoflavone status after soy intake (25), controlling for the isoflavone bioavailability 
phenotypes of human subjects may optimize conditions to observe isoflavone effects.
           Several studies have observed that isoflavones had no effect on improving 
blood lipid profile, including a recent meta-analysis (1). For example, dietary intake of 
isoflavone-rich (80.4 mg isoflavone aglucones/d; n=24) or isoflavone-poor soy protein (4.4 
mg isoflavones/d; n=24) for 6 mo did not improve circulating lipid and lipoprotein 
concentrations in perimenopausal women or in subjects who were mildly 
hypercholesterolemic (n=30) (26).  Hamsters fed isoflavones (0.02 g/100g diet) for 5 wk did 
not differ from the casein control in total cholesterol, triglycerides or HDL-C (p>0.05) (27).  
These studies did not attempt to control for interindividual variability in isoflavone 
bioavailability. 
 
 
 
86
           Soyasaponins, associated with soy protein in addition to isoflavones, were also 
assessed for cholesterol-lowering effect.  A diet containing 2.4 g group B soyasaponins/kg 
(saponin concentration similar to that in 25% soy protein diet) caused significantly lesser 
plasma total cholesterol and non-HDL-C (by 20 and 33%) in ten 11–12 wk old female 
Golden Syrian hamsters compared with those fed casein (20). High producers of a putative 
fecal saponin metabolite had lesser total cholesterol/HDL-C compared with low producers. In 
the present study, high and low saponin metabolite producers did not differ in plasma lipid 
status (data not shown), and the dietary saponin content (1.1 g/kg) was ~half that shown to be 
effective in lessening cholesterol in a previous study (20).  Thus, isoflavones and not 
saponins were the main modifiers of plasma lipids, but both components vary among soy 
protein sources and may contribute to lessening of plasma cholesterol by soy protein. 
         The cholesterol-lessening effect of soy protein in hamsters largely depended on 
the extent of apparent absorption of isoflavones, which varies according to distinct 
phenotypes. These urinary isoflavone excretion phenotypes may be defined according to 
glycitein or total isoflavone excretion over a given period.  These isoflavone absorption 
phenotypes are probably determined by gut microbial ecology, but isoflavone degrading 
microbial species and other factors determining this relatively stable variability in isoflavone 
absorption remain to be identified.  Studies of effects of isoflavones in humans and animal 
models might be better served by taking interindividual variability in isoflavone absorption 
into account, as it seems to be a factor that could be controlled for.  
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FIGURES 
 
FIGURE 1 Display of the ranked values of the percentage of ingested isoflavone dose 
excreted in hamster urine at w 1 for (A) Daidzein, (B) Glycitein, (C) Genistein, and (D) Total 
Isoflavone. Rankings on the x-axis were different for each isoflavone. According to the 
percentage of ingested dose of glycitein excreted in urine, high and low urinary excretion 
phenotypes were identified by a natural break point in (B) Glycitein. 
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FIGURE 2 Hierarchical clustering based on hamster urinary excretion of total isoflavone in 
w 1.  A dendrogram of the urinary excretion of total isoflavone in w 1 was computed by 
complete-link clustering which divided all hamsters (except hamsters 1 and 2) into four 
clusters (as indicated by the dotted line). Dissimilarity between the clusters was defined as 
the maximum dissimilarities between members. The height at which two cases joined a 
single group indicated their dissimilarity.  
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FIGURE 3 Scatterplots of hamster urinary excretion of ingested dose of isoflavones for w 1.  
Pairwise relationships were compared among urinary excretion of glycitein, daidzein, 
genistein, and total isoflavones in bivariate scatterplots A-F. The numbers indicate groupings 
of individuals as defined in Fig. 2 (hierarchical clustering). Group 2 constituted low urinary 
excreters of all isoflavones whereas Group 3 were high urinary excreters of all isoflavones 
compared with the other groups. Groups 1 and 4 fell between groups 2 and 3 and had no 
‘universal’ ordering. 
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FIGURE 4 Stability of urinary glycitein excretion within hamsters between w 1 and 4.  The 
vertical axis is the hamster number (1-39) ranked in order by urinary glycitein excretion at w 
1. The fraction of ingested dose of glycitein excreted in urine in each hamster is represented 
on the horizontal axis and the horizontal line connects w 1 and w 4 measurements for each 
hamster.  
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TABLES 
 
TABLE 1 
 
Urinary Isoflavone Recoveries in Female Golden Syrian Hamsters According to 
Urinary Glycitein Excretion Phenotypes (high and low) in Weeks 1 and 41 
Urinary 
excretion 
phenotype  
___________ % ingested dose recovered in urine over 24 h________
 Daidzein Genistein Glycitein Total isoflavone
Week 1     
High (n=11) 27.7±5.9 25.1±4.2 88.2±8.2# 45.8±5.9 
Low (n=27)    8.8±3.8*      7.9±3.6*       27.2±11.2*#  11.9±4.8*  
All (n=38) 14.3±4.8   12.9±3.2   44.8±9.3#      21.7±6.1 
Week 4     
High (n=9) 25.9±6.8 23.8±3.2    82.8±9.7#    43.8±6.2   
Low (n=29)    9.1±4.1*          8.2±4.1*        29.9±10.7*#  13.8±4.9*  
All (n=38) 13.1±5.2       11.9±3.9     42.4±11.3#   20.9±5.2   
 
1 Values represent means± SEM.  * Different from high excreter, #different from daidzein and 
genistein, P <0.05. 
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TABLE 2 
 
Urinary Isoflavone Recoveries in Female Golden Syrian Hamsters According to 
Urinary Total Isoflavone Excretion Phenotypes in Weeks 1 and 41 
Urinary 
excretion 
phenotype  
____________% ingested dose recovered in urine over 24 h________
 Daidzein Genistein Glycitein Total isoflavone
Week 1     
High (n=7) 30.8±5.2     26.2±3.8 86.9±7.3# 46.0±5.8 
Low (n=23)    8.1±3.9*      7.5±3.9*    25.9±9.9*#  11.1±5.1*  
All (n=30) 13.4±4.8 11.8±4.1    40.1±10.5# 19.2±6.2    
Week 4     
High (n=9) 28.9±5.7  25.9±4.1    87.9±8.1# 44.9±6.1 
Low (n=21)    8.3±4.2*          7.6±3.9*      26.5±8.9*#  12.3±9.3*  
All (n=30) 14.5±4.8         13.1±4.2   44.9± 9.9# 22.1±7.0     
 
1 Values represent means± SEM.  * Different from high excreter, #different from daidzein and 
genistein, P <0.05. 
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TABLE 3 
 
Plasma Cholesterol Level in Female Golden Syrian Hamsters Fed Casein or Soy 
Protein with Different Urinary Isoflavone Excretion Phenotypes1, 2 
 
 ___________________ mmol/L_________________       
                                  N      Total 
cholesterol 
HDL 
cholesterol  
Non- HDL3 
cholesterol 
Triglyceride  
 
Non- HDL/HDL 
cholesterol  
Casein                      10 5.71±0.88 3.02±0.42      2.41±0.91    1.19±0.32       0.79±0.28        
Soy Protein               38     4.68±0.72*     2.79±0.57      1.67±0.69*   1.15±0.57 
 
0.59±0.19*        
Week 1 
          High glycitein  11 
 
 
4.21±0.71*    
 
2.81±0.63      
 
1.18±0.75*   
 
1.12±0.42 
 
0.41±0.21*        
 
          Low glycitein   27     
 
4.88±0.81      
 
2.78±0.37      
 
1.87±0.88     
 
1.16±0.31 
 
0.67±0.33        
Week 4 
          High glycitein   9      
 
4.01±0.81*    
 
2.61±0.69      
 
1.09±0.65*   
 
1.09±0.38 
 
 
0.39±0.27*        
     
          Low glycitein  29      
 
4.93±0.79      
 
2.92±0.48      
 
1.92±0.83     
 
1.13±0.36 
 
0.69±0.38        
Week 1 
High total isoflavone  7      
 
4.10±0.56*   
 
2.75±0.51 
 
1.12±0.62*   
 
1.13±0.59 
 
0.41±0.39*        
 
Low total isoflavone 23   
 
5.01±0.83      
 
2.51±0.48      
 
2.23±0.87     
 
1.17±0.31 
 
 
0.88±0.37         
Week 4 
High total isoflavone  9     
 
3.98±0.57*   
 
2.65±0.39 
 
1.11±0.52*   
 
1.03±0.61 
 
0.40±0.41*        
 
Low total isoflavone  21 
 
5.21±0.73      
 
2.62±0.50      
 
2.33±0.77     
 
1.12±0.35 
 
0.87±0.39        
 
1Values represent means± SEM. * Different from casein, P <0.05. 
2Urinary isoflavone excretion clusters were determined by either glycitein (Fig. 1) or total 
isoflavone excretion (Fig. 2). 
3Represents the VLDL+IDL+LDL fractions (by difference: Total-HDL). 
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GENERAL CONCLUSIONS  
 
Because much recent work published on soy protein and its component isoflavones 
did not support a significant role for soy isoflavones in cholesterol-lowering effects of soy 
protein, the more investigations which should be focused on bioavailability are needed. In 
addition to the valid animal model, hamster which has close cholesterol metabolism and 
similarities in bioavailability compared to humans, was established, the further study, 
especially for interindividual variability in isoflavone bioavailability, was considered deeply 
in our present project.     
 First of all, the cholesterol-lessening effect of soy protein in hamsters largely 
depended on the extent of apparent absorption of isoflavones, which varies according to 
distinct phenotypes. These urinary isoflavone excretion phenotypes may be defined 
according to glycitein or total isoflavone excretion over a given period.  These isoflavone 
absorption phenotypes are probably determined by gut microbial ecology. At meantime, 
apparent absorbability of isoflavones varied stably among individuals.  To identify urinary 
isoflavone excretion phenotypes and investigate the effect of these phenotypes on plasma 
lipids after soy protein feeding, we identified two distinct urinary isoflavone excretion 
phenotypes based on urinary glycitein or total isoflavone excretion in hamsters using 
pairwise correlation plots analysis and hierarchical cluster test. With either grouping method, 
the high isoflavone excretion phenotype showed significantly greater urinary daidzein, 
genistein, glycitein and total isoflavones and marginally greater fecal glycitein excretion than 
the low excretion phenotype at given period.  
              By McNemar’s test, we also found that the low glycitein urinary excretion 
phenotype was more stable and the high glycitein urinary excretion phenotype was less 
stable. More meaningfully, hamsters fed the soy protein diet had significantly lower total and 
non-HDL cholesterol and non-HDL/HDL ratios compared with the control. Hamsters of the 
high urinary isoflavone excretion phenotype had significantly lower total, non-HDL 
cholesterol and non-HDL/HDL ratios than did the low isoflavone excretion phenotype and 
the control group. Total and non-HDL cholesterol were significantly negatively correlated 
with urinary daidzein, glycitein and total isoflavone excretion.  
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   These illustrated that the distinct urinary isoflavone excretion phenotypes are major 
determinants of cholesterol-lowering efficacy of soy protein and suggest that absorbability 
may be an important controllable variable in studies of effects of soy protein and isoflavones. 
Urinary isoflavone excretion phenotypes predicted the cholesterol-lowering efficacy of soy 
protein. Isoflavone absorbability, probably due to gut microbial ecology, is an important 
controllable variable in studies of effects of soy protein on blood lipids. Studies of effects of 
isoflavones in humans and animal models might be better served by taking interindividual 
variability in isoflavone absorption into account. 
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